Rivaroxaban in Peripheral Artery Disease After Revascu

New England Journal of Medicine

382, 1994-2004

DOI: 10.1056/nejmoa2000052

Citation Report

#	Article	IF	Citations
1	Antithrombotic Strategies for Patients With Coronary and Lower Extremity Peripheral Artery Diseases: A Narrative Review. Expert Review of Cardiovascular Therapy, 2020, 18, 881-889.	2.7	8
2	The Impact of Low-Dose Anticoagulation Therapy on Peripheral Artery Disease: Insights From the VOYAGER Trial. Cardiovascular Research, 2020, 116, e156-e158.	13.5	2
3	Chez les sujets avec maladie artérielle périphérique symptomatique ayant eu une revascularisation aux membres inférieurs, est-ce que le rivaroxaban 2,5 mg deux fois par jour combiné à l'aspirine réduit le risque composite d'ischémie aigüe des membres inférieurs, d'amputation majeure de cause vasculaire, d'infarctus du myocarde, d'accident vasculaire cérébral ischémique ou de décès d'origine cardiovasculaire, comparativement à l'aspirine seule, tout en étant sécuritaire ?. Revue De Medecine Interne, 2020, 41, 571-572.	0.5	0
4	Contemporary Review of Antithrombotic Therapy in Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2020, 13, e009584.	6.2	25
5	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. JAMA Cardiology, 2021, 6, 21-29.	16.3	89
6	ASCVD Risk and Statin Use in PAD: Implementing a New Approach to an Old Problem. Journal of the American College of Cardiology, 2020, 76, 265-267.	12.0	5
7	Pathologic Disparities Between Peripheral Artery Disease and Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 1982-1989.	7.9	133
8	Antithrombotische Kombination wirksamer als ASS allein : Sekundärprävention der peripheren Verschlusskrankheit. MMW Fortschritte Der Medizin, 2020, 162, 12-13.	0.0	0
9	Rivaroxaban in Peripheral Artery Disease After Revascularization. New England Journal of Medicine, 2020, 383, 2089-2090.	76.6	13
10	Direct Oral Anticoagulants: Evidence and Unresolved Issues. Lancet, The, 2020, 396, 1767-1776.	96.9	180
11	Polyvascular Disease: A Narrative Review of Current Evidence and a Consideration of the Role of Antithrombotic Therapy. Atherosclerosis, 2020, 315, 10-17.	7.0	34
12	Prevention of Stroke in Patients With Chronic Coronary Syndromes or Peripheral Arterial Disease. European Heart Journal Supplements, 2020, 22, M26-M34.	2.9	14
13	Combining Antiplatelet and Anticoagulant Therapy in Cardiovascular Disease. Hematology, 2020, 2020, 642-648.	2.5	55
14	VOYAGER PAD Contributes to Medical Therapy for Peripheral Artery Disease. Journal of Vascular Surgery, 2020, 72, 1843-1844.	3.4	1
15	Aspirin and Low-Dose Rivaroxaban – The Dual Pathway Concept in Patients With Stable Atherosclerotic Disease: A Comprehensive Review. Expert Review of Cardiovascular Therapy, 2020, 18, 577-585.	2.7	3
16	Rivaroxaban for the Prevention of Major Adverse Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease. Future Cardiology, 2020, 16, 597-611.	1.2	2
17	Genetic Risk Factors for Venous Thromboembolism. Expert Review of Hematology, 2020, 13, 971-981.	2.7	108
18	Necessity of Antiaggregation and Anticoagulation and Its Prognostic Impact: A Cardiologist's View. Chirurgische Gastroenterologie Interdisziplinar, 2020, 36, 264-273.	1.7	4

#	Article	IF	Citations
19	Antithrombotic Therapy in Myocardial Infarction: Historic Perils and Current Challenges—A 70-Year Journey. Thrombosis and Haemostasis, 2020, 120, 1352-1356.	4.6	10
20	New Horizons for Mortality Risk Stratification in PAD: Are Targeted Multiplex Proteomics the Next Step?. Atherosclerosis, 2020, 311, 98-99.	7.0	1
21	Pleiotropic Actions of Factor Xa Inhibition in Cardiovascular Prevention: Mechanistic Insights and Implications for Anti-Thrombotic Treatment. Cardiovascular Research, 2021, 117, 2030-2044.	13.5	57
22	Scientific Surgery August 2020 BJS. British Journal of Surgery, 2020, 107, 1232-1232.	3.9	0
23	The Role of Aspirin After High-Risk Percutaneous Coronary Intervention: The Ticagrelor With Aspirin or Alone in High-Risk Patients After Coronary Intervention Clinical Trial Experience. Interventional Cardiology Clinics, 2020, 9, 489-498.	1.1	2
24	Possible Effect of Direct Oral Anti-Coagulant for Preventing Long Stenting Lesion From In-Stent Restenosis in Femoropopliteal Segment: Case Report With Angioscopy Findings. SAGE Open Medical Case Reports, 2020, 8, 2050313X20945535.	0.8	0
25	Antiplatelet Therapy Following Peripheral Arterial Interventions. Circulation: Cardiovascular Interventions, 2020, 13, e009727.	6.2	13
26	Vascular Protective Effect of Aspirin and Rivaroxaban Upon Endothelial Denudation of the Mouse Carotid Artery. Scientific Reports, 2020, 10, 1-14.	5.2	6
27	Updates on the Use of Direct Oral Anticoagulants for the Management of Chronic Conditions. Pharmacy Today, 2020, 26, 44-58.	0.0	0
28	The Age of Randomized Clinical Trials: Three Important Aspects of Randomized Clinical Trials in Cardiovascular Pharmacotherapy With Examples From Lipid, Diabetes, and Antithrombotic Trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 453-459.	5.0	7
29	Short-Term Clinical Outcomes of Single Versus Dual Antiplatelet Therapy After Infrainguinal Endovascular Treatment for Peripheral Arterial Disease. Journal of Clinical Medicine, 2020, 9, 3515.	3.8	10
30	Review on Characteristics and Analytical Methods of Rivaroxaban. Critical Reviews in Analytical Chemistry, 2022, 52, 865-877.	7.9	24
31	Rivaroxaban and Aspirin in Peripheral Artery Disease Lower Extremity Revascularization. Circulation, 2020, 142, 2219-2230.	24.6	101
32	A Bon VOYAGER for Peripheral Artery Disease. New England Journal of Medicine, 2020, 382, 2047-2048.	76.6	11
33	Highlights From the First Ever Virtual American College of Cardiology World Congress of Cardiology 2020 (ACC.20/WCC). Cardiovascular Research, 2020, 116, e75-e77.	13.5	0
34	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. Thrombosis and Haemostasis, 2020, 120, 1004-1024.	4.6	236
35	Review of ACC 2020 Late-Breaking Trials in Interventional Cardiology. Cardiovascular Revascularization Medicine, 2020, 21, 905-911.	1.6	2
36	Current and Emerging Drug Treatment Strategies for Peripheral Arterial Disease. Expert Opinion on Pharmacotherapy, 2020, 21, 1603-1616.	3.5	12

#	Article	IF	Citations
37	Rationale and Design for the Study Apixaban Versus ClopidoGRel on a Background of Aspirin in Patient Undergoing InfraPoPliteal Angioplasty for Critical Limb Ischemia: AGRIPPA Trial. American Heart Journal, 2020, 227, 100-106.	3.3	19
38	Systematic Literature Review of Randomized Trials Comparing Antithrombotic Therapy Following Revascularization Procedures in Patients With Peripheral Artery Disease. Angiology, 2020, 71, 773-790.	2.4	3
39	The Voyager PAD Trial – New Path for Post-Revascularisation PAD Patients. European Journal of Vascular and Endovascular Surgery, 2020, 59, 699-700.	3.2	8
40	Vascular Vantage Point. Journal of Vascular Surgery, 2020, 71, 1449.	3.4	0
41	Rivaroxaban Reduces Ischaemic Events in Patients With PAD. Nature Reviews Cardiology, 2020, 17, 322-322.	62.4	1
42	Important Considerations for Trials for Peripheral Arterial Disease: Lessons Learned From the Paclitaxel Mortality Signal: A Report on Behalf of the Registry Assessment for Peripheral Interventional Devices (RAPID) Paclitaxel Pathways Program. American Heart Journal, 2021, 232, 71-83.	3.3	10
43	Peripheral Arterial Disease and Intermittent Claudication in Coronary Heart Disease Patients. International Journal of Cardiology, 2021, 322, 227-232.	3.2	27
44	Applications of Physiologically Based Pharmacokinetic Modeling of Rivaroxaban—Renal and Hepatic Impairment and Drug-Drug Interaction Potential. Journal of Clinical Pharmacology, 2021, 61, 656-665.	2.4	33
45	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2021. Diabetes Care, 2021, 44, S125-S150.	20.9	475
46	The Future of Aspirin Therapy in Cardiovascular Disease. American Journal of Cardiology, 2021, 144, S40-S47.	2.4	5
47	Vaskuläre Rehabilitation. Gefasschirurgie, 2021, 26, 13-20.	0.4	0
48	A National Canadian Survey of Antithrombotic Therapy After Urgent and Emergent Limb Revascularization. Canadian Journal of Cardiology, 2021, 37, 504-507.	3.8	13
49	The Pharmacology, Efficacy, and Safety of Rivaroxaban in Obese Patient Populations. American Journal of Cardiovascular Drugs, 2021, 21, 283-297.	3.7	14
50	One-Year Outcomes of Heparin-Bonded Stent-Graft Therapy for Real-World Femoropopliteal Lesions and the Association of Patency With the Prothrombotic State Based on the Prospective, Observational, Multicenter Viabahn Stent-Graft Placement for Femoropopliteal Diseases Requiring Endovascular Therapy (VANQUISH) Study. Journal of Endovascular Therapy, 2021, 28, 123-131.	2.1	36
51	Sex Bias in Surgical Research. , 2021, .		0
52	Antithrombotische Therapie Nach Peripherer Revaskularisation. Deutsche Medizinische Wochenschrift, 2021, 146, 136-140.	0.3	6
53	How to Manage Patients With Polyvascular Atherosclerotic Disease. Position Paper of the International Union of Angiology. International Angiology, 2021, 40, 29-41.	1.8	10
54	Methods of Decreasing the Risk of Repeat Interventions in Patients After Arterial Revascularization. Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, 2021, 27, 169-175.	0.2	0

#	Article	IF	Citations
55	Medical Therapy for Secondary Prevention of Atherothrombotic Events in Peripheral Artery Disease. Heart International, 2021, 15, 14-19.	2.6	2
56	Prognostic Value of the CHA2DS2-VASc Score After Endovascular Therapy for Femoral Popliteal Artery Lesions. Journal of Atherosclerosis and Thrombosis, 2021, 28, 1153-1160.	3.7	11
57	Evidence-Experience Gap and Future Perspective on the Treatment of Peripheral Artery Disease. Journal of Atherosclerosis and Thrombosis, 2021, 28, 1251-1259.	3.7	4
58	Oral Anticoagulant and Antiplatelet Therapy for Peripheral Arterial Disease: A Meta-Analysis of Randomized Controlled Trials. Clinical and Applied Thrombosis/Hemostasis, 2021, 27, 1076029621996810.	2.2	8
59	Healthcare Resource Utilization and Costs of Major Atherothrombotic Vascular Events Among Patients With Peripheral Artery Disease After Revascularization. Journal of Medical Economics, 2021, 24, 402-409.	3.0	12
60	Amputation as an Anticipated Consequence of Peripheral Artery Disease and Ways to Improve the Prognosis of Limb Salvage. Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, 2021, 27, 182-190.	0.2	4
61	Towards Personalized Antithrombotic Management With Drugs and Devices Across the Cardiovascular Spectrum. European Heart Journal, 2022, 43, 940-958.	14.7	18
62	Drug-Coated Stent Implantation vs. Bypass Surgery for In-Stent Occlusion After Femoropopliteal Stenting. Heart and Vessels, 2021, 36, 646-653.	1.8	9
63	Selección de lo mejor del año 2020 sobre el tratamiento antitrombótico para el cardiólogo clínico. REC: CardioClinics, 2021, 56, 54-58.	0.3	0
64	Are There Alternatives to Dual Antiplatelet Therapy After Stenting of Peripheral Arteries?. Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, 2021, 27, 22-27.	0.2	1
65	Response by Waissi et Al Regarding Article, "Elevated Lp(a) (Lipoprotein[a]) Levels Increase Risk of 30-Day Major Adverse Cardiovascular Events in Patients Following Carotid Endarterectomy". Stroke, 2021, 52, e66-e67.	9.1	0
66	CT Perfusion in Peripheral Arterial Disease—Hemodynamic Differences Before and After Revascularisation. European Radiology, 2021, 31, 5507-5513.	6.4	17
67	Anterograde and Retrograde Approach With Through-and-Through Wiring Technique to Treat a Ruptured and Extremely Tortuous Giant Popoliteal Artery Aneurism. Vascular and Endovascular Surgery, 2021, 55, 668-672.	0.9	1
68	Medical Therapy for Cardiovascular and Limb-Related Risk Reduction in Critical Limb Ischemia. Vascular Medicine, 2021, 26, 210-224.	2.3	8
69	Paclitaxel-Coated Devices: Safety and Efficacy Are in the PVI of the Beholder. Journal of the American Heart Association, 2021, 10, e020289.	5.8	2
70	PAD Screening: Why? Whom? When? How? – A Systematic Review. Vasa - European Journal of Vascular Medicine, 2021, 50, 85-91.	2.7	10
71	Factors Associated With Infrainguinal Bypass Graft Patency at 1-Year; A Retrospective Analysis of a Single Centre Experience. Perfusion (United Kingdom), 2022, 37, 276-283.	1.8	5
72	A Narrative Review of Low-Dose Rivaroxaban in Patients With Atherothrombotic Cardiovascular Disease: Vascular Protection Beyond Anticoagulation. Cardiovascular Diagnosis and Therapy, 2021, 11, 13041-13141.	2.1	10

#	Article	IF	Citations
73	Contemporary Trends in Hospital Admissions and Outcomes in Patients With Critical Limb Ischemia. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007539.	5.6	67
74	Low Dose Rivaroxaban for Atherosclerotic Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 2021, 11, 608247.	5.3	9
75	Antiplatelet and Anticoagulation Therapy After Revascularization for Lower Extremity Artery Disease: A National Survey and Literature Overview. Journal of Cardiovascular Surgery, 2021, 62, 59-70.	0.8	4
76	Antithrombotic Therapy in Diabetes: Which, When, and for How Long?. European Heart Journal, 2021, 42, 2235-2259.	14.7	61
77	Omega-3 Polyunsaturated Fatty Acid Supplementation in Patients With Lower Extremity Arterial Disease. Journal of the American College of Nutrition, 2022, 41, 383-391.	4.1	0
78	Rekanalisationen im femoropoplitealen und kruropedalen Segment bei pAVK. Gefäßmedizin Scan - Zeitschrift Für Angiologie Gefäßchirurgie Diagnostische Und Interventionelle Radiologie, 2021, 8, 53-68.	0.0	0
79	Abnormal Vascular Physiology in the Lower Extremities as a Risk Factor for Ischemic Stroke and Mortality. Journal of Osteopathic Medicine, 2021, 121, 463-470.	1.5	4
80	The Efficacy and Safety of Direct Oral Anticoagulants Plus Aspirin in Symptomatic Lower Extremity Peripheral Arterial Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Thrombosis and Thrombolysis, 2021, 52, 904-913.	2.2	6
81	Femoral-Popliteal Peripheral Artery Disease: From Symptom Presentation to Management and Treatment Controversies. Progress in Cardiovascular Diseases, 2021, 65, 15-22.	9.7	11
82	Successful Peripheral Vascular Intervention in Patients With High-Risk Comorbidities or Lesion Characteristics. Current Cardiology Reports, 2021, 23, 1-13.	4.5	1
83	The Epidemiology of Lower Extremity Amputations, Strategies for Amputation Prevention, and the Importance of Patient-Centered Care. Seminars in Vascular Surgery, 2021, 34, 54-58.	2.8	52
84	The Current Status of Drug-Coated Devices in Lower Extremity Peripheral Artery Disease Interventions. Progress in Cardiovascular Diseases, 2021, 65, 23-28.	9.7	6
85	The Pharmacology, Efficacy, and Safety of Rivaroxaban in Renally Impaired Patient Populations. Journal of Clinical Pharmacology, 2021, 61, 1010-1026.	2.4	25
86	Gemeinsam Klug Entscheiden – Periphere Arterielle Verschlusskrankheit. Gefasschirurgie, 2021, 26, 206-211.	0.4	0
87	Prevention and Management of Urgent/Emergent Limb Ischemia. Current Cardiology Reports, 2021, 23, 1-7.	4.5	2
88	Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants Combined With Antiplatelet Drugs for Patients With Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Vascular, 2022, 30, 97-104.	1.1	2
89	Managing the Coagulation System in Patients With Arterial Disease. Journal of Vascular Surgery, 2021, 73, 940-941.	3.4	0
90	Asymptomatic Peripheral Artery Disease: Silent but Deadly. Progress in Cardiovascular Diseases, 2021, 65, 2-8.	9.7	26

#	Article	IF	Citations
91	Location of Recurrent Cardiovascular Events and Anticardiolipin Antibodies. European Journal of Clinical Investigation, 2021, 51, e13533.	4.4	3
92	Peripheral Arterial Disease in Persons With Diabetic Foot Ulceration: A Current Comprehensive Overview. Current Diabetes Reviews, 2021, 17, 474-485.	3.0	32
93	The Effect of Deep Vein Thrombosis on Major Adverse Limb Events in Diabetic Patients: A Nationwide Retrospective Cohort Study. Scientific Reports, 2021, 11, 1-9.	5.2	6
94	Disparities Between International Guidelines (AHA/ESC/ESVS/ESVM/SVS) Concerning Lower Extremity Arterial Disease: Consensus of the French Society of Vascular Medicine (SFMV) and the French Society for Vascular and Endovascular Surgery (SCVE). Annals of Vascular Surgery, 2021, 72, 1-56.	1.8	50
95	Cilostazol: A Review of Basic Mechanisms and Clinical Uses. Cardiovascular Drugs and Therapy, 2022, 36, 777-792.	4.1	83
96	The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization. JACC: Cardiovascular Interventions, 2021, 14, 796-802.	5.0	8
97	Clinical Considerations After Endovascular Therapy of Peripheral Artery Disease. Expert Review of Cardiovascular Therapy, 2021, 19, 369-378.	2.7	2
98	Progress in Aorta and Peripheral Cardiovascular Disease Research. Cardiovascular Research, 2021, 117, 2045-2053.	13.5	7
99	Genetically Proxied Inhibition of Coagulation Factors and Risk of Cardiovascular Disease: A Mendelian Randomization Study. Journal of the American Heart Association, 2021, 10, e019644.	5.8	31
100	Medical Management of Risk Factors for Vascular Disease. Surgery, 2021, 39, 248-256.	0.6	1
101	Aspirin at 120: Retiring, Recombining, or Repurposing?. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12516.	3.3	15
102	Direct Oral Anticoagulants: From Randomized Clinical Trials to Real-World Clinical Practice. Frontiers in Pharmacology, 2021, 12, 684638.	5.3	79
103	Antithrombotic Regimens in Females With Symptomatic Lower Extremity Peripheral Arterial Disease: Protocol for a Systematic Review and Meta-Analysis. BMJ Open, 2021, 11, e042980.	2.7	0
104	Efficacy and Safety of Rivaroxaban Therapy for Patients With Peripheral Artery Disease: A Systematic Review and Meta-Analysis. Vascular and Endovascular Surgery, 2021, 55, 712-720.	0.9	5
105	Review New Concepts in Pharmacotherapy for Peripheral Arterial Disease. Current Opinion in Cardiology, 2021, 36, 720.	2.2	3
106	The Voyager PAD Trial in a Surgical Perspective: A Debate. European Journal of Vascular and Endovascular Surgery, 2021, 61, 721-722.	3.2	7
107	Considerations for Use of Direct Oral Anticoagulants in Arterial Disease. Research and Practice in Thrombosis and Haemostasis, 2021, 5, e12502.	3.3	3
108	Rationale and Design for the Study of Rivaroxaban to Reduce Thrombotic Events, Hospitalization and Death in Outpatients With COVID-19: The PREVENT-HD Study. American Heart Journal, 2021, 235, 12-23.	3.3	40

#	Article	IF	Citations
109	Diabetes Mellitus Was Not Associated With Lower Amputation-Free Survival After Open Revascularization for Chronic Limb-Threatening Ischemia – A Nationwide Propensity Score Adjusted Analysis. Vascular Medicine, 2021, 26, 507-514.	2.3	7
110	Interplay Between Inflammation and Thrombosis in Cardiovascular Pathology. Nature Reviews Cardiology, 2021, 18, 666-682.	62.4	1,001
111	Assessment and Management of Peripheral Arterial Disease: What Every Cardiologist Should Know. Heart, 2021, 107, 1835-1843.	4.9	39
112	Do We Have a Unified Consensus on Antithrombotic Management of PAD?. International Angiology, 2021, 40, 229-239.	1.8	1
113	Reply to “the VOYAGER PAD Trial in Surgical Perspective: A Debate”. European Journal of Vascular and Endovascular Surgery, 2021, 61, 723-724.	3.2	0
114	Medical Management of PAD: Expand or Consolidate?. Annals of the Academy of Medicine, Singapore, 2021, 50, 376-378.	1.1	0
115	Antiplatelet Therapy With or Without Anticoagulant Therapy for Lower Extremity Peripheral Artery Disease: A Systematic Review. American Journal of Health-System Pharmacy, 2021, 78, 2132-2141.	1.4	1
116	Efficacy and Safety of Dual-Pathway Inhibition in Patients With Cardiovascular Disease: A Meta-Analysis of 49 802 Patients From 7 Randomized Trials. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 519-528.	5.0	27
117	2020 Asian Pacific Society of Cardiology Consensus Recommendations on Antithrombotic Management for High-Risk Chronic Coronary Syndrome. European Cardiology Review, 2021, 16, e26.	2.4	13
118	CIRSE Standards of Practice on Below-the-Knee Revascularisation. CardioVascular and Interventional Radiology, 2021, 44, 1309-1322.	2.3	16
119	Antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit. Gefasschirurgie, 2021, 26, 415-428.	0.4	1
120	Cost-Effectiveness Analysis of Ankle-Brachial Index Screening in Patients With Coronary Artery Disease to Optimize Medical Management. Journal of Vascular Surgery, 2021, 74, 2030-2039.e2.	3.4	6
121	Advances in Revascularization for Peripheral Artery Disease: Revascularization in PAD. Circulation Research, 2021, 128, 1885-1912.	15.7	228
122	Bench-to-Bedside in Vascular Medicine: Optimizing the Translational Pipeline for Patients With Peripheral Artery Disease. Circulation Research, 2021, 128, 1927-1943.	15.7	15
123	Medical Therapy Following Urgent/Emergent Revascularization in Peripheral Artery Disease Patients (Canadian Acute Limb Ischemia Registry [CANALISE I]). CJC Open, 2021, 3, 1325-1332.	1.8	5
124	How to Fill the GAPS-I in Secondary Prevention: Application of a Strategy Based on GLP1 Analogues, Antithrombotic Agents, PCSK9 Inhibitors, SGLT2 Inhibitors and Immunomodulators. Panminerva Medica, 2022, 64, 265-273.	0.8	7
125	New Directions in Therapeutic Angiogenesis and Arteriogenesis in Peripheral Arterial Disease. Circulation Research, 2021, 128, 1944-1957.	15.7	181
126	Association of Heart Failure With Outcomes Among Patients With Peripheral Artery Disease: Insights From EUCLID. Journal of the American Heart Association, 2021, 10, e018684.	5.8	31

#	Article	IF	Citations
127	Effectiveness of Blood Lipid Management in Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 77, 3016-3027.	12.0	52
128	Evidence-Based Recommendations for Medical Management of Peripheral Artery Disease. Journal of Atherosclerosis and Thrombosis, 2021, 28, 573-583.	3.7	25
129	Epidemiology of Peripheral Artery Disease and Polyvascular Disease. Circulation Research, 2021, 128, 1818-1832.	15.7	594
130	Additive Prognosis of Clinical Presentation in Revascularized Peripheral Arterial Disease Patients. Minerva Cardiology and Angiology, 2022, 70, 413-420.	1.3	4
131	Long-Term Outcome for Covered Endovascular Reconstruction of Aortic Bifurcation for Aortoiliac Disease: A Single-Center Experience. Journal of Endovascular Therapy, 2021, 28, 906-913.	2.1	32
132	Contemporary Medical Management of Peripheral Artery Disease. Circulation Research, 2021, 128, 1868-1884.	15.7	153
133	Meta-Analysis of Anticoagulation Therapy for the Prevention of Cardiovascular Events in Patients With Peripheral Arterial Disease. American Journal of Cardiology, 2021, 148, 165-171.	2.4	3
134	Lower Extremity Peripheral Artery Disease Without Chronic Limb-Threatening Ischemia: A Review. JAMA - Journal of the American Medical Association, 2021, 325, 2188-2198.	37.0	198
135	Is This the Beginning of End for Warfarin in Bioprosthetic Mitral Valve Recipients With Atrial Fibrillation? – New Insights From RIVER Trial. Indian Heart Journal, 2021, 73, 516-517.	2.3	0
136	Antithrombotic Therapy to Reduce Mortality in Patients With Atherosclerosis: 2 Pathways to a Single Goal. Journal of the American College of Cardiology, 2021, 78, 24-26.	12.0	3
137	Angiographic Flow Velocity Predicts Lower Limb Outcomes After Endovascular Therapy: Application of the Frame Count Method. Vascular Medicine, 2022, 27, 39-46.	2.3	2
138	Antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit. Geriatrie Up2date, 2021, 3, 195-205.	0.1	0
139	Total Ischemic Event Reduction With Rivaroxaban After Peripheral Arterial Revascularization in the VOYAGER PAD Trial. Journal of the American College of Cardiology, 2021, 78, 317-326.	12.0	50
140	Wider Lens, Sharper Focus. Journal of the American College of Cardiology, 2021, 78, 327-329.	12.0	0
141	Comparison of the Physicochemical Properties, Aqueous Solubility, and Oral Bioavailability of Rivaroxaban-Loaded High-Pressure Homogenised and Shirasu Porous Glass Membrane Emulsified Solid Self-Nanoemulsifying Drug Delivery Systems. Journal of Molecular Liquids, 2022, 346, 117057.	5.4	31
142	Prophylactic Anticoagulation in Sinus Rhythm for Stroke Prevention in Cardiovascular Disease: Contemporary Meta-Analysis of Large Randomized Trials. European Journal of Preventive Cardiology, 2022, 28, 1939-1948.	6.1	1
143	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 78, 14-23.	12.0	52
144	Sex Disparities in Long-Term Mortality After Paclitaxel Exposure in Patients With Peripheral Artery Disease: A Nationwide Claims-Based Cohort Study. Journal of Clinical Medicine, 2021, 10, 2978.	3.8	7

#	Article	IF	Citations
145	Endovascular Relining of Chronically Occluded Infrainguinal Venous Bypass Grafts. Annals of Vascular Surgery, 2021, 74, 339-343.	1.8	4
146	2020. Japanese Journal of Cardiovascular Surgery, 2021, 50, 294-296.	0.1	0
147	Angioplasty of Flow-Limiting Stenosis Reduces Aortic and Brachial Blood Pressure in Patients With Peripheral Artery Disease. Journal of the American Heart Association, 2021, 10, e019724.	5.8	5
148	The Challenge of Choosing in Cardiovascular Risk Management. Netherlands Heart Journal, 2022, 30, 47-57.	2.6	7
149	Antithrombotische Therapie Bei Diabetes Mellitus. Diabetologe, 2021, 17, 825-833.	0.2	0
150	Antithrombotic Therapy in Patients With Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. International Journal of Molecular Sciences, 2021, 22, 7113.	5.9	17
151	Medical Management of Peripheral Arterial Disease: Deciphering the Intricacies of Therapeutic Options. CJC Open, 2021, 3, 936-949.	1.8	9
152	Antithrombotic Therapies in Aortic and Peripheral Arterial Diseases in 2021: A Consensus Document From the ESC Working Group on Aorta and Peripheral Vascular Diseases, the ESC Working Group on Thrombosis, and the ESC Working Group on Cardiovascular Pharmacotherapy. European Heart Journal, 2021, 42, 4013-4024.	14.7	135
153	Outcomes After Receipt of Neuraxial or Regional Anesthesia Instead of General Anesthesia for Lower Limb Revascularization Surgery: Protocol for a Systematic Review and Meta-Analysis. JMIR Research Protocols, 2021, 10, e32170.	1.8	3
154	Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial. Circulation, 2021, 144, 1104-1116.	24.6	48
155	Antithrombotic Treatment for Peripheral Arterial Occlusive Disease. Deutsches Ärzteblatt International, 2021, 118, 528-535.	3.5	7
156	Comprehensive Assessment of Current Management Strategies for Patients With Diabetes and Chronic Limb-Threatening Ischemia. Clinical Diabetes, 2021, 39, 358-388.	4.0	4
157	Antithrombosis Stewardship Efforts to De-Escalate Inappropriate Combined Therapy in Outpatient Clinics. Journal of Thrombosis and Thrombolysis, 2022, 53, 436-445.	2.2	13
158	Vascular Endothelial Tissue Factor Contributes to Trimethylamine N-Oxide-Enhanced Arterial Thrombosis. Cardiovascular Research, 2022, 118, 2367-2384.	13.5	109
159	Randomized Clinical Trial to Evaluate a Routine Full Anticoagulation Strategy in Patients With Coronavirus Infection (SARS-CoV2) Admitted to Hospital: Rationale and Design of the ACTION (AntiCoagulaTIon cOroNavirus)–Coalition IV Trial. American Heart Journal, 2021, 238, 1-11.	3.3	25
160	Covered Stent Grafts for Relining of Chronically Occluded Femoro-Popliteal Bypasses in Frail Patients. Clinical Case Reports (discontinued), 2021, 9, e04647.	0.8	5
161	Efficacy and Safety of Rivaroxaban Compared With Other Therapies Used in Patients With Peripheral Artery Disease Undergoing Peripheral Revascularization: A Systematic Literature Review and Network Meta-Analysis. Cardiovascular Therapeutics, 2021, 2021, 8561350.	3.0	8
162	Rivaroxaban in Patients With Recent Peripheral Artery Revascularization and Renal Impairment: The VOYAGER PAD Trial. Journal of the American College of Cardiology, 2021, 78, 757-759.	12.0	11

#	Article	IF	Citations
163	Trends in Use of Cardioprotective Medication in Peripheral Artery Disease: A Nationwide Study. Journal of the American Heart Association, 2021, 10, e020333.	5.8	8
164	Low-Dose Rivaroxaban Plus Aspirin in Older Patients With Peripheral Artery Disease Undergoing Acute Limb Revascularization: Insights From the VOYAGER PAD Trial. European Heart Journal, 2021, 42, 4040-4048.	14.7	23
165	Long Term Survival and Limb Salvage in Patients With Non-Revascularisable Chronic Limb Threatening Ischaemia. European Journal of Vascular and Endovascular Surgery, 2021, 62, 225-232.	3.2	35
166	Incidence of Major Atherothrombotic Vascular Events Among Patients With Peripheral Artery Disease After Revascularization. Annals of Vascular Surgery, 2021, 75, 217-226.	1.8	13
167	Low-Dose Rivaroxaban and Aspirin Among Patients With Peripheral Artery Disease: A Meta-Analysis of the COMPASS and VOYAGER Trials. European Journal of Preventive Cardiology, 2022, 29, e181-e189.	6.1	38
168	Lesson Learned From the COMPASS and VOYAGER PAD Trials: Dual Pathway Inhibition as a New Antithrombotic Paradigm?. European Journal of Preventive Cardiology, 2022, 29, e178-e180.	6.1	3
169	A Systematic Review and Meta-Analysis of Outcomes After Acute Limb Ischemia in Patients With Cancer. Journal of Vascular Surgery, 2021, 74, 1033-1040.e1.	3.4	17
170	Pharmacological Management of Obstructive Peripheral Arterial Disease: Two Case Reports. Hospital Practice (1995), 2021, 49, 379-383.	1.2	0
171	Role of Diabetes in Stroke: Recent Advances in Pathophysiology and Clinical Management. Diabetes/Metabolism Research and Reviews, 2022, 38, e3495.	8.4	39
172	Editor's Choice – External Applicability of the COMPASS and VOYAGER-PAD Trials on Patients With Symptomatic Lower Extremity Artery Disease in France: The COPART Registry. European Journal of Vascular and Endovascular Surgery, 2021, 62, 439-449.	3.2	33
173	Low-Dose Rivaroxaban Plus Aspirin for Elderly Patients With Symptomatic Peripheral Artery Disease: Is It Worth the Bleeding Risk?. European Heart Journal, 2021, 42, 4049-4052.	14.7	6
174	Characteristics of Atherosclerosis in Femoropopliteal Artery and Its Clinical Relevance. Atherosclerosis, 2021, 335, 31-40.	7.0	36
175	Impact of Dual Antiplatelet Therapy After Lower Extremity Revascularization for Chronic Limb-Threatening Ischemia. Journal of Vascular Surgery, 2021, 74, 1327-1334.	3.4	9
176	Decision Tree Analysis to Predict the Risk of Intracranial Haemorrhage After Mild Traumatic Brain Injury in Patients Taking DOACs. American Journal of Emergency Medicine, 2021, 50, 388-393.	2.5	21
177	Practical Cardiology. , 2022, .		44
178	Peripheral Arterial Disease—A Different Kind of Arterial Disease? The Role of Antiplatelet Therapy in the Prevention and Treatment of Limb Ischemia. , 2021, .		0
179	Indian Journal of Vascular and Endovascular Surgery. Indian Journal of Vascular and Endovascular Surgery, 2021, 8, S25-S30.	0.3	0
180	Antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit. Gefäßmedizin Scan - Zeitschrift Für Angiologie Gefäßchirurgie Diagnostische Und Interventionelle Radiologie, 2020, 07, 291-301.	0.0	1

#	Article	IF	Citations
181	Diabetes Mellitus and Outcomes of Lower Extremity Revascularization for Peripheral Artery Disease. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 8, 298-306.	4.9	21
182	Reducing Residual Thrombotic Risk in Patients With Peripheral Artery Disease: Impact of the COMPASS Trial. Drugs in Context, 2020, 9, 1-15.	2.5	6
183	A Brief Overview of Medical Management Options in Peripheral Arterial Disease. International Journal of Infectious Diseases and Research, 2021, .	0.0	0
184	A Protocol for DUAL Pathway Inhibition (Low-Dose Rivaroxaban and Aspirin) as Compared to Aspirin Only to Improve Endothelial Function in Peripheral Artery Disease. Medicine, Case Reports and Study Protocols, 2021, 2, e0163.	0.1	1
185	A Systematic Review and Meta-Analysis on the Efficacy and Safety of Direct Oral Anticoagulants in Patients With Peripheral Artery Disease. Annals of Vascular Surgery, 2022, 80, 1-11.	1.8	11
186	Reduction in Acute Limb Ischemia With Rivaroxaban Versus Placebo in Peripheral Artery Disease After Lower Extremity Revascularization: Insights From VOYAGER PAD. Circulation, 2021, 144, 1831-1841.	24.6	44
187	Efficacy and Safety of Vorapaxar by Intensity of Background Lipid-Lowering Therapy in Patients With Peripheral Artery Disease: Insights From the TRA2P-TIMI 50 Trial. Journal of the American Heart Association, 2021, 10, e021412.	5.8	3
188	Assessment of Nonfatal Myocardial Infarction as a Surrogate for All-Cause and Cardiovascular Mortality in Treatment or Prevention of Coronary Artery Disease: A Meta-Analysis of Randomized Clinical Trials. JAMA Internal Medicine, 2021, 181, 1575-1587.	16.3	51
189	Real-World Antithrombotic Treatment Variability in Patients Undergoing Peripheral Vascular Intervention: Insights From the VQI Registry. American Heart Journal, 2022, 244, 31-35.	3.3	6
190	Of Life and Limb: Addition of Low-Dose Rivaroxaban for Secondary Prevention After Peripheral Artery Disease Surgery. Circulation, 2021, 144, 1117-1119.	24.6	0
191	Impact of High On-Treatment Platelet Reactivity After Angioplasty in Patients With Critical Limb Ischemia. Vascular Pharmacology, 2021, 141, 106925.	3.4	6
192	Role of Von Willebrand Factor in Venous Thromboembolic Disease. JVS Vascular Science, 2022, 3, 17-29.	1.8	40
193	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus – Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen Gesellschaft für Gefäßchirurgie und Gefäßmedizin (DGG). Diabetologie Und Stoffwechsel, 2021, 16, S351-S361.	0.2	3
194	Combination Anticoagulant or P2Y12 Inhibitor With Low-Dose Aspirin Versus Low-Dose Aspirin Alone in Patients at Risk or With Documented Coronary And/Or Peripheral Artery Disease. Current Medical Research and Opinion, 2022, 38, 27-34.	2.9	2
195	Safety and Effectiveness of Paclitaxel Drug-Coated Devices in Peripheral Artery Revascularization: Insights From VOYAGER PAD. Journal of the American College of Cardiology, 2021, 78, 1768-1778.	12.0	32
196	Antiproliferative Device Coatings: Efficacy Without Adverse Drug Effect?. Journal of the American College of Cardiology, 2021, 78, 1779-1781.	12.0	0
197	Medical Management of Peripheral Artery Disease. Cardiology Clinics, 2021, 39, 471-482.	1.4	9
198	The Voyager PAD Study: A Game Changer in Medical Treatment After Endovascular Recanalization on Peripheral Arterial Disease?. CardioVascular and Interventional Radiology, 2020, 43, 1587-1588.	2.3	1

#	Article	IF	Citations
199	A COMPASS for VOYAGERs With Revascularized Peripheral Artery Disease. Vasa - European Journal of Vascular Medicine, 2020, 49, 427-428.	2.7	0
200	Endovascular Interventions for Peripheral Arterial Disease Have to Be Integrated in a Concept of Total Cardiovascular Care by Angiologists to Improve Patients and Limbs Prognosis. Vasa - European Journal of Vascular Medicine, 2020, 49, 345-347.	2.7	0
201	Improving Medical Adherence and Antithrombotic Management for Patients With Chronic Limb Threatening Ischaemia in Singapore. Annals of the Academy of Medicine, Singapore, 2021, 50, 795-797.	1.1	5
202	Angioscopic Ulcerated Plaques in the Femoropopliteal Artery Associated With Impaired Infrapopliteal Runoff. Journal of Vascular and Interventional Radiology, 2022, 33, 97-103.e1.	2.2	4
203	Dissecting Femoropopliteal Dissections: Time to FLIPI the Script?. JACC: Cardiovascular Interventions, 2021, 14, 2402-2404.	5.0	0
204	Klinische Angiologie. Springer Reference Medizin, 2025, .	0.0	16
205	Lipid-Lowering and Anti-Thrombotic Therapy in Patients With Peripheral Arterial Disease: European Atherosclerosis Society/European Society of Vascular Medicine Joint Statement. Atherosclerosis, 2021, 338, 55-63.	7.0	25
206	Place des anticoagulants dans l'artériopathie oblitérante des membres inférieurs. Bulletin De L'Academie Nationale De Medecine, 2021, 205, 1098-1104.	0.3	0
207	Clinical Implications and Cost-Effectiveness Analysis of Rivaroxaban in Patients With Coronary Artery Disease or Peripheral Arterial Disease in the Netherlands. Journal of Medical Economics, 2021, 24, 1231-1239.	3.0	6
208	Lipid-Lowering and Anti-Thrombotic Therapy in Patients With Peripheral Arterial Disease. Vasa - European Journal of Vascular Medicine, 2021, 50, 401-411.	2.7	25
209	Concerning New Standards of Treatment of the Peripheral Arteries Diseases on Background of Modern Recommendations and Data of Clinical Investigations, Taking Into Account a Significance of Prophylaxis of Unfavorable Events With the Extremity and Cardio-VA. The Ukrainian Journal of Clinical Surgery, 2020, 87, 102-104.	0.1	0
210	Sequential Design and Analysis in the Randomized Clinical Trial: A Historical Perspective. Sequential Analysis, 2020, 39, 295-306.	1.0	1
211	Anticoagulation in Peripheral Artery Disease: Are We There Yet?. Vascular and Endovascular Review, 2020, .	0.6	3
212	Mortality, Cardiovascular and Limb Events in Patients With Symptomatic Lower Extremity Artery Disease and Diabetes. Angiology, 2022, 73, 528-538.	2.4	9
213	Treatment of Aortic and Iliac Artery Occlusion by Catheter Thrombolysis Combined With Catheter Thrombectomy and Aortic Bifurcation Endovascular Stent Reconstruction. Case Reports in Vascular Medicine, 2021, 2021, 6084226.	0.5	2
214	A Systematic Review of Thromboelastography Utilization in Vascular and Endovascular Surgery. Journal of Vascular Surgery, 2022, 75, 1107-1115.	3.4	28
215	High Lipoprotein(a) Is Associated With Major Adverse Limb Events After Femoral Artery Endarterectomy. Atherosclerosis, 2022, 349, 196-203.	7.0	28
216	A Single-Center, Randomized, Double-Blind Study of 94 Patients Undergoing Surgery for Cerebral Glioma to Compare Postoperative Thromboprophylaxis With and Without Rivaroxaban. Medical Science Monitor, 2022, 28, 0.	2.4	11

#	Article	IF	Citations
217	Joint Statement From the European Atherosclerosis Society and European Society of Vascular Medicine Focuses on Patients With Peripheral Arterial Disease. Atherosclerosis, 2022, 340, 48-50.	7.0	2
218	Applying Randomised Trials to the Real World: A VOYAGER of Discovery. European Journal of Vascular and Endovascular Surgery, 2022, 63, 295.	3.2	1
219	Direct Oral Anticoagulants: A Review for the Non-Specialist. Hematology Reports, 2021, 13, 9239.	2.2	10
220	Arzneiverordnungs-Report 2021. , 2021, .		51
221	Ten-Year Clinical Follow-Up Following Bare-Nitinol Stent Implantation for Femoropopliteal Artery Disease. Journal of Atherosclerosis and Thrombosis, 2022, 29, 1448-1457.	3.7	11
222	Update on the Pathophysiology and Medical Treatment of Peripheral Artery Disease. Nature Reviews Cardiology, 2022, 19, 456-474.	62.4	217
223	Key Aspects of Drug Therapy in Vascular Surgery. Angiologiia I Sosudistaia Khirurgiia = Angiology and Vascular Surgery, 2021, 27, 17-25.	0.2	0
224	Navigating the Passage for Better Understanding and Prognosis for Acute Limb Ischemia After Lower-Extremity Revascularization. Circulation, 2021, 144, 1842-1844.	24.6	2
225	Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation, 2022, 145, e153-e639.	24.6	5,101
226	Textbook of Acute Trauma Care. , 2022, .		18
227	Aspects of Antithrombotic and Anticoagulant Therapies in Patients Undergoing Endovascular Procedures for Lower Extremity Arterial Disease. Orvosi Hetilap, 2022, 163, 98-108.	0.9	1
228	A Review of Antithrombotic Therapies for Patients With Chronic Peripheral Arterial Disease and After Revascularization. Angiology, 2022, 73, 197-206.	2.4	1
229	Pharmacodynamic Profiles of Dual-Pathway Inhibition With or Without Clopidogrel Versus Dual Antiplatelet Therapy in Patients With Atherosclerotic Disease. Thrombosis and Haemostasis, 2022, 122, 1341-1351.	4.6	21
230	Effect of Postoperative Antithrombotic Therapy on Lower Extremity Outcomes After Infrapopliteal Bypass for Chronic Limb-Threatening Ischemia. Journal of Vascular Surgery, 2022, 75, 1696-1706.e4.	3.4	8
231	Traitement antithrombotique dans l'artériopathie oblitérante des membres inférieurs : pourquoi et pour qui ?. Archives Des Maladies Du Coeur Et Des Vaisseaux - Pratique, 2022, 2022, 3-8.	0.0	0
232	Peripheral Arterial Disease. , 2022, .		0
233	Impact of Cardiac Function on Loss of Patency in Patients With Peripheral Artery Disease Presenting the Femoropopliteal Lesions Endovascularly Treated With New-Generation Devices. Journal of Endovascular Therapy, 2023, 30, 75-83.	2.1	3
234	Antiplatelet Therapy in Cardiovascular Disease: Current Status and Future Directions. British Journal of Clinical Pharmacology, 2022, 88, 2686-2699.	3.0	91

#	Article	IF	Citations
235	Vorapaxar for Prevention of Major Adverse Cardiovascular and Limb Events in Peripheral Artery Disease. Journal of Cardiovascular Pharmacology and Therapeutics, 2022, 27, 10742484211056115.	2.9	9
236	DCRM Multispecialty Practice Recommendations for the Management of Diabetes, Cardiorenal, and Metabolic Diseases. Journal of Diabetes and Its Complications, 2022, 36, 108101.	3.4	60
237	Team-Based Care in Patients With Chronic Limb-Threatening Ischemia. Current Cardiology Reports, 2022, 24, 217-223.	4.5	6
238	Building Your Peripheral Artery Disease Toolkit: Medical Management of Peripheral Artery Disease in 2022. Canadian Journal of Cardiology, 2022, 38, 634-644.	3.8	11
239	The OAC3-PAD Risk Score Predicts Major Bleeding Events One Year After Hospitalisation for Peripheral Artery Disease. European Journal of Vascular and Endovascular Surgery, 2022, 63, 503-510.	3.2	59
240	Interventionelle Therapie der PAVK - "How I do it". CardioVasc, 2021, 21, 42-52.	0.0	0
241	10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes—2022. Diabetes Care, 2022, 45, S144-S174.	20.9	500
242	Importance of the Results of VOYAGER PAD Trial for Clinical Practice. , 2021, .		0
243	Dual Pathway of Inhibition and Vascular Protection in Patients With Atherosclerotic Disease. , 2021, .		0
244	Management of Diabetic Foot Disease. , 2022, .		4
245	Antithrombotic Therapy in Peripheral Artery Disease: Risk Stratification and Clinical Decision Making. Canadian Journal of Cardiology, 2022, 38, 654-661.	3.8	7
246	Sex Differences in Peripheral Artery Disease. Circulation Research, 2022, 130, 496-511.	15.7	190
247	State-of-the-Art Mini Review: Dual-Pathway Inhibition to Reduce Arterial and Venous Thromboembolism. Thrombosis and Haemostasis, 2022, 122, 1279-1287.	4.6	17
248	When and How to Combine Antiplatelet and Anticoagulant Drugs?. Hamostaseologie, 2022, 42, 073-079.	1.5	24
249	Revascularisation for Symptomatic Peripheral Artery Disease: External Applicability of the VOYAGER PAD Trial. European Journal of Vascular and Endovascular Surgery, 2022, 63, 285-294.	3.2	22
250	The Anti-Coronavirus Therapies (ACT) Trials: Design, Baseline Characteristics, and Challenges. CJC Open, 2022, 4, 568-576.	1.8	7
251	The Impact of Atrial Fibrillation on One-Year Mortality in Patients With Severe Lower Extremity Arterial Disease. Journal of Clinical Medicine, 2022, 11, 1936.	3.8	4
252	Prevention of Arterial and Venous Thrombotic Events in Symptomatic Peripheral Arterial Disease Patients After Lower Extremity Revascularization in the VOYAGER PAD Trial: Dual Anticoagulant/Antiplatelet Regimen vs Antiplatelet Therapy Alone. Journal of Thrombosis and Haemostasis, 2022, 20, 1193-1205.	5.0	15

#	Article	IF	Citations
253	Pharmacological Profile of Asundexian, a Novel, Orally Bioavailable Inhibitor of Factor XIa. Journal of Thrombosis and Haemostasis, 2022, 20, 1400-1411.	5.0	115
254	Escalation of Antithrombotic Therapy Should Be Considered in the Presence of Intraluminal Prosthetic Graft Thrombus Following Endovascular Aneurysm Repair. EJVES Vascular Forum, 2022, 56, 1-5.	1.0	8
255	Platelet P2Y12 Inhibiting Therapy in Adjunct to Vascular Dose of Rivaroxaban or Aspirin: A Pharmacodynamic Study of Dual Pathway Inhibition vs. Dual Antiplatelet Therapy. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 728-737.	5.0	23
256	Predicting Major Bleeding Events in Patients With Peripheral Arterial Disease: The OAC3-PAD Risk Score. Gefasschirurgie, 2022, 27, 208-212.	0.4	4
257	PRINCESS Without a Crown...The Challenge to Generate Evidence in the King's Class of Vascular Surgery. European Journal of Vascular and Endovascular Surgery, 2022, 63, 851.	3.2	0
258	Risk Factors and Consequences of Graft Infection After Femoropopliteal Bypass: A 25-Year Experience. Journal of Vascular Surgery, 2022, 76, 248-254.	3.4	19
259	Safety and Effectiveness of Endovascular Therapy for the Treatment of Peripheral Artery Disease in Patients With and Without Diabetes Mellitus. Angiology, 2022, 73, 956-966.	2.4	16
260	Direct Oral Anticoagulants and Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2022, 42, 553-564.	7.9	13
261	Circulating Biomarkers in Lower Extremity Artery Disease. European Cardiology Review, 2022, 17, e09.	2.4	15
262	"Author's Reply" Validity of Current Treatment Guideline for Patients With Limb-Threatening Ischemia With Antiphospholipid Syndrome. Journal of Cardiology Cases, 2022, 26, 166-167.	0.6	0
263	Ceramides and Phospholipids in Plasma Extracellular Vesicles Are Associated With High Risk of Major Cardiovascular Events After Carotid Endarterectomy. Scientific Reports, 2022, 12, 1-13.	5.2	25
264	Independent Predictors of Major Adverse Cardiovascular Events at 3 Years After Aortoiliac Stent Implantation. Journal of Vascular and Interventional Radiology, 2022, 33, 826-833.e1.	2.2	2
265	DOACs and Atherosclerotic Cardiovascular Disease Management: Can We Find the Right Balance Between Efficacy and Harm. Current Atherosclerosis Reports, 2022, 24, 457-469.	7.3	4
266	Platelet Reactivity Testing in Peripheral Artery Disease. American Journal of Health-System Pharmacy, 2022, 79, 1312-1322.	1.4	3
267	Increased Thrombogenicity Is Associated With Revascularization Outcomes in Patients With Chronic Limb-Threatening Ischemia. Journal of Vascular Surgery, 2022, 76, 513-522.e3.	3.4	1
268	Evaluation of Definitions for Oral Anticoagulant-Associated Major Bleeding: A Population-Based Cohort Study. Thrombosis Research, 2022, 213, 57-64.	2.9	9
269	Antithrombotic Treatment in Lower Extremity Peripheral Arterial Disease. Frontiers in Cardiovascular Medicine, 2021, 8, 773214.	3.2	9
270	Unexplained Arterial Thrombosis: Approach to Diagnosis and Treatment. Hematology, 2021, 2021, 76-84.	2.5	28

#	Article	IF	Citations
271	Ischaemic and Bleeding Risk in Atrial Fibrillation With and Without Peripheral Artery Disease and Efficacy and Safety of Full- and Half-Dose Edoxaban vs. Warfarin: Insights From ENGAGE AF-TIMI 48. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 695-706.	5.0	10
272	Мультифокальный атеросклероз: фокус на профилактике развития ишемических событий. Russian Journal of Cardiology, 2022, 26, 4808.	1.9	8
273	Prevalence of VOYAGER PAD Trial Exclusion Criteria in Unselected Patients Undergoing Lower Limb Revascularization. International Angiology, 2022, 41, 56-62.	1.8	5
274	Medical Optimization of the Peripheral Artery Disease Patient. Seminars in Vascular Surgery, 2022, 35, 113-123.	2.8	3
275	A Comprehensive Review on Antithrombotic Therapy for Peripheral Artery Disease. Seminars in Vascular Surgery, 2022, 35, 124-131.	2.8	13
276	Management of Chronic Peripheral Artery Disease Patients With Indication for Endovascular Revascularization. Vasa - European Journal of Vascular Medicine, 2022, 51, 121-137.	2.7	27
277	Position Paper on the Diagnosis and Treatment of Peripheral Arterial Disease (PAD) in People With Diabetes Mellitus. Experimental and Clinical Endocrinology and Diabetes, 2022, 130, S127-S136.	1.9	3
278	Improvement in Walking Impairment Following Surgical and Endovascular Revascularization: Insights From VOYAGER PAD. Vascular Medicine, 2022, 27, 343-349.	2.3	9
279	Phoenix Atherectomy for Patients With Peripheral Artery Disease. EuroIntervention, 2022, 18, e432-e442.	4.9	45
280	Deletion of MicroRNA-21 Impairs Neovascularization Following Limb Ischemia: From Bedside to Bench. Frontiers in Cardiovascular Medicine, 2022, 9, 826478.	3.2	9
281	Endovascular Management of Complex Tibial Lesions. Seminars in Vascular Surgery, 2022, 35, 190-199.	2.8	5
282	European Stroke Organisation (ESO) Guideline on Pharmacological Interventions for Long-Term Secondary Prevention After Ischaemic Stroke or Transient Ischaemic Attack. European Stroke Journal, 2022, 7, I-II.	5.8	227
283	Mono or Dual Antiplatelet Therapy for Treating Patients With Peripheral Artery Disease After Lower Extremity Revascularization: A Systematic Review and Meta-Analysis. Pharmaceuticals, 2022, 15, 596.	6.1	18
284	Management of Patients With Embolic Stroke of Unknown Source: Interpreting the Evidence in the Light of Clinical Judgement. Current Neurology and Neuroscience Reports, 2022, 22, 389-393.	8.7	5
285	Antithrombotische Therapie Bei Diabetes Mellitus. Die Kardiologie, 2022, 16, 253-262.	1.4	0
286	Optimal Conduit Choice for Open Lower Extremity Bypass in Chronic Limb-Threatening Ischemia. Seminars in Vascular Surgery, 2022, 35, 172-179.	2.8	14
287	Differential Inhibition of Platelet Reactivity by Dual Therapy With Aspirin and Low-Dose Rivaroxaban in Peripheral Arterial Disease: A Pilot Study. Frontiers in Cardiovascular Medicine, 2022, 9, 865166.	3.2	5
288	Canadian Cardiovascular Society 2022 Guidelines for Peripheral Arterial Disease. Canadian Journal of Cardiology, 2022, 38, 560-587.	3.8	134

#	Article	IF	Citations
289	Konservative Therapie der peripheren arteriellen Verschlusskrankheit. Der Internist, 2022, 63, 579-583.	0.7	0
290	Interventional Cardiology. , 2022, .		252
291	Urinary Neutrophil Gelatinase-Associated Lipocalin (NGAL) Can Potentially Predict Vascular Complications and Reliably Risk Stratify Patients With Peripheral Arterial Disease. Scientific Reports, 2022, 12, 1-8.	5.2	7
292	One-Year Health Status Outcomes Following Early Invasive and Noninvasive Treatment in Symptomatic Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2022, 15, e011506.	6.2	19
293	Clinical Experience With Dual Pathway Inhibition Therapy: Case Series and Mini Review. European Heart Journal - Case Reports, 2022, 6, ytac201.	0.6	1
294	Total Cardiovascular and Limb Events and the Impact of Polyvascular Disease in Chronic Symptomatic Peripheral Artery Disease. Journal of the American Heart Association, 2022, 11, e025504.	5.8	14
295	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus. Die Diabetologie, 2022, 18, 402-411.	0.1	0
296	Endovascular Treatment of Infrainguinal Peripheral Arterial Disease (PAD): Update on Stent Technology. Techniques in Vascular and Interventional Radiology, 2022, 25, 100840.	1.6	6
297	Efficacy and Safety Considerations With Dose-Reduced Direct Oral Anticoagulants: A Review. JAMA Cardiology, 2022, 7, 747-759.	16.3	52
298	Feasibility of the Complete Endovascular Reconstruction of the Trifurcation (CERT) Technique for Revascularisation in Chronic Limb Threatening Ischemia. Vascular and Endovascular Surgery, 2022, 56, 15385744221106275.	0.9	0
299	From Purpose to Impact: Harnessing the Elements to Improve Peripheral Artery Disease Outcomes. Journal of the American Heart Association, 2022, 11, e025912.	5.8	0
300	Sex-Based Differences in Outcomes Following Peripheral Artery Revascularization: Insights From VOYAGER PAD. Journal of the American Heart Association, 2022, 11, e024655.	5.8	16
301	International Union of Angiology Position Statement on Perioperative Drug and Hemostasis Management in Vascular Surgery. International Angiology, 2022, 41, 420-432.	1.8	4
302	P2Y12 Inhibitor Monotherapy Is Associated With Superior Outcomes as Compared With Aspirin Monotherapy in Chronic Limb-Threatening Ischemia. Journal of Vascular Surgery, 2022, 76, 1053-1059.	3.4	5
303	Grundlagen des perioperativen Umgangs mit direkten oralen Antikoagulanzien. Die Anaesthesiologie, 2022, 71, 565-576.	1.3	4
304	A Retrospective Analysis of COVID-19 Patients Presented With Vascular Problems: A Single Center Experience. International Surgery Journal, 2022, 9, 1315-1325.	0.2	0
305	Major Lower Limb Amputations and Amputees in an Aging Population in Southwest Finland 2007–2017. Clinical Interventions in Aging, 2022, 17, 925-936.	4.2	9
306	Rivaroxaban and Risk of Venous Thromboembolism in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Revascularization. JAMA Network Open, 2022, 5, e2215580-e2215580.	10.2	19

#	Article	IF	Citations
307	New VOYAGER PAD Data: Should Patients With Both PAD and CKD Get Rivaroxaban?. , 2022, .		0
308	Rivaroxaban 2.5 mg Twice Daily Plus Aspirin Reduces Venous Thromboembolism in Patients With Chronic Atherosclerosis. Circulation, 2022, 145, 1875-1877.	24.6	8
309	Assessment of the Burden of Disease for Patients With Peripheral Artery Disease Undergoing Revascularization in England. Vascular Medicine, 2022, 27, 440-449.	2.3	7
310	Potential Reduction in Adverse Events and Cost With Novel Anticoagulants Among Patients With Acute Limb Ischemia. International Journal of Vascular Medicine, 2022, 2022, 3786815.	1.0	1
311	Impact of Anticoagulation/Antiplatelet Therapy on Femoropopliteal Bypass Graft Outcomes. Journal of Vascular Surgery, 2022, 76, 1045-1052.e1.	3.4	9
312	Ticagrelor or Clopidogrel for Dual Antiplatelet Therapy After Transcarotid and Transfemoral Stenting of the Carotid Artery: Are We Ready for a Randomized Controlled Trial?. Journal of Vascular Surgery, 2022, 76, 307-309.	3.4	1
313	Peripheral Arterial Disease (Pathophysiology, Presentation, Prevention/Management). , 2022, .		1
314	Direct Oral Anticoagulants and Peripheral Arterial Disease. Galenika Medical Journal, 2022, 1, 76-79.	0.1	0
315	Nastal čas nahradit monoterapii kyselinou acetylsalicylovou v sekundární prevenci účinnější léčbou?. Cor Et Vasa, 2022, 64, 305-309.	0.3	0
316	Clinical Outcomes After Endovascular Revascularisation of the Femoropopliteal Arterial Segment in Patients With Anticoagulant Versus Antiplatelet Therapy: A Single-Centre Retrospective Cohort Study. Journal of Cardiovascular Development and Disease, 2022, 9, 207.	2.9	1
317	Periphere arterielle Verschlusskrankheit bei Menschen mit Diabetes. Die Diabetologie, 2022, 18, 549-560.	0.1	0
318	Australian Guideline on Diagnosis and Management of Peripheral Artery Disease: Part of the 2021 Australian Evidence-Based Guidelines for Diabetes-Related Foot Disease. Journal of Foot and Ankle Research, 2022, 15, 1-25.	2.7	27
319	Prognostic Impact of Atrial Fibrillation on the Outcomes of Peripheral Artery Disease According to Preoperative Symptoms for Endovascular Revascularization. Heart and Vessels, 2023, 38, 106-113.	1.8	0
320	Percutaneous Coronary Intervention With Peripheral Artery Disease in the Contemporary Era: Still Life or Limb?. Atherosclerosis, 2022, 355, 45-47.	7.0	1
321	Critical Limb Ischemia: Update for the Cardiovascular Anesthesiologist. Journal of Cardiothoracic and Vascular Anesthesia, 2022, 36, 3939-3944.	2.1	4
322	Aortic Calcification Index Predicts Mortality and Cardiovascular Events in Operatively Treated Patients With Peripheral Artery Disease: A Prospective PURE ASO Cohort Follow-Up Study. Journal of Vascular Surgery, 2022, 76, 1657-1666.e2.	3.4	9
323	One Year Clinical Outcomes of Rutherford 6 Chronic Limb Threatening Ischemia Patients Undergoing Lower Limb Endovascular Revascularisation From Singapore. CVIR Endovascular, 2022, 5, 32.	2.5	5
324	Neutrophil-to-Lymphocyte Ratio Predicts Restenosis After Drug-Coated Balloon Therapy for Femoropopliteal Artery Lesions: A Retrospective Study. Frontiers in Cardiovascular Medicine, 2022, 9, 868656.	3.2	9

#	Article	IF	Citations
325	Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights From the MARINER Trial. TH Open, 2022, 06, e177-e183.	1.8	1
326	Outcomes of Hospitalized Patients Undergoing Endoscopic Retrograde Cholangiopancreatography (ERCP) With and Without a History of Peripheral Artery Disease. Cureus, 2022, 14, e26585.	1.3	0
327	Effect of Direct Oral Anticoagulants Versus Warfarin on Patency in High-Risk Bypass Patients. Annals of Vascular Surgery, 2023, 88, 63-69.	1.8	4
328	Low-Dose Aspirin for the Prevention of Atherothrombosis Across the Cardiovascular Risk Continuum. Cardiology Plus, 2022, 7, 64.	1.7	1
329	Current and Novel Emerging Medical Therapies for Peripheral Artery Disease: A Literature Review. Advanced Pharmaceutical Bulletin, 2023, 13, 259-268.	3.7	11
330	Current Management of Peripheral Artery Disease: Focus on Pharmacotherapy. Drugs, 2022, 82, 1165-1177.	15.5	14
331	Determination of Rivaroxaban in Rat Plasma by Ultra-High-Performance Liquid Chromatography–Q-Orbitrap High-Resolution Mass Spectrometry and Its Application to a Pharmacokinetic Study. Biomedical Chromatography, 2022, 36, e5491.	1.8	4
332	Managing Thrombotic Risk in Patients With Diabetes. Cardiovascular Diabetology, 2022, 21, 1-16.	15.7	19
333	2022 ESC Guidelines on Cardiovascular Assessment and Management of Patients Undergoing Non-Cardiac Surgery. European Heart Journal, 2022, 43, 3826-3924.	14.7	1,123
334	Low-Dose Aspirin and Rivaroxaban Combination Therapy to Overcome Aspirin Non-Sensitivity in Patients With Vascular Disease. Frontiers in Cardiovascular Medicine, 2022, 9, 912114.	3.2	7
335	Intravascular Lithotripsy in Calcified Peripheral Lesions: Single-Center JEN-Experience. International Journal of Angiology, 2023, 32, 011-020.	1.1	13
336	Variability of Antiplatelet Response in Patients With Peripheral Artery Disease. Journal of Vascular Surgery, 2023, 77, 208-215.e3.	3.4	24
337	State-of-the-Art Endovascular Therapies for the Femoropopliteal Segment: Are We There Yet?. Journal of the Society for Cardiovascular Angiography & Interventions, 2022, 1, 100439.	2.3	14
338	Programmable DARPin-Based Receptors for the Detection of Thrombotic Markers. Nature Chemical Biology, 2022, 18, 1125-1134.	16.4	21
339	Approaches to Peripheral Artery Disease in Diabetes: Are There Any Differences?. International Journal of Environmental Research and Public Health, 2022, 19, 9801.	4.2	49
340	Advances for the Treatment of Lower Extremity Arterial Disease Associated With Diabetes Mellitus. Frontiers in Molecular Biosciences, 2022, 9, 929718.	4.5	5
341	Antithrombotic Therapy for Symptomatic Peripheral Arterial Disease: A Systematic Review and Network Meta-Analysis. Drugs, 2022, 82, 1287-1302.	15.5	33
342	Fluid Dynamics and Mass Transport in Lower Limb Vessels: Effects on Restenosis. , 2022, .		0

#	Article	IF	Citations
343	The Top Five Papers of 2020 for General Internists. Canadian Journal of General Internal Medicine, 2022, 17, 86-93.	0.2	0
344	Use of Direct Oral Anticoagulant and Associated Bleeding and Thrombotic Complication After Lower Extremity Bypass. Journal of the American College of Surgeons, 2022, 235, 778.	2.5	1
345	Aspirin Resistance in Vascular Disease: A Review Highlighting the Critical Need for Improved Point-of-Care Testing and Personalized Therapy. International Journal of Molecular Sciences, 2022, 23, 11317.	5.9	44
346	Are Factor Xa Inhibitors Efficacious for Ischemic Stroke Prevention in Patients Without Atrial Fibrillation? Evidence From Randomized Clinical Trials. Canadian Journal of Cardiology, 2023, 39, 187-197.	3.8	1
347	Variability in Antithrombotic Therapy After Infrainguinal Lower Extremity Bypass. Annals of Vascular Surgery, 2023, 88, 51-62.	1.8	6
348	Peripheral Artery Disease and the Risk of Venous Thromboembolism. Vasa - European Journal of Vascular Medicine, 2022, 51, 365-371.	2.7	14
349	Comparison of Aspirin and Rivaroxaban Plus Aspirin in the Management of Stable Coronary Artery Disease or Peripheral Artery Disease: A Systematic Review of Randomized Controlled Trials. International Journal of General Medicine, 2022, 15, 7201-7208.	2.5	8
350	Emerging Roles of Protease-Activated Receptors in Cardiometabolic Disorders. Journal of Cardiology, 2023, 81, 337-346.	3.8	14
351	Dual Pathway Inhibition as Compared to Acetylsalicylic Acid Monotherapy in Relation to Endothelial Function in Peripheral Artery Disease, a Phase IV Clinical Trial. Frontiers in Cardiovascular Medicine, 2022, 9, 979819.	3.2	3
352	Risk Factors of Patients With Peripheral Arterial Disease. Contemporary Cardiology, 2022, .	0.0	0
353	Putting It All Together: An Algorithmic Approach to Treat Patients With Peripheral Arterial Disease. Contemporary Cardiology, 2022, .	0.0	0
354	Pharmacologic Interventions in Patients With Peripheral Arterial Disease. Contemporary Cardiology, 2022, .	0.0	0
355	Preoperative Evaluation and Perioperative Management of Patients Undergoing Major Vascular Surgery. Vascular Medicine, 2022, 27, 496-512.	2.3	36
356	Efficacy and Safety of Rivaroxaban Versus Placebo After Lower Extremity Bypass Surgery: A Post Hoc Analysis of a "CASPAR Like" Outcome From VOYAGER PAD. Clinical Cardiology, 2022, 45, 1143-1146.	3.1	11
357	Antithrombotic Therapy in Peripheral Arterial Disease. Frontiers in Cardiovascular Medicine, 2022, 9, 927645.	3.2	10
358	Factor XI Inhibitors: Cardiovascular Perspectives. European Heart Journal, 2023, 44, 280-292.	14.7	66
359	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus – Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen Gesellschaft für Gefäßchirurgie und Gefäßmedizin (DGG). Diabetologie Und Stoffwechsel, 2022, 17, S354-S364.	0.2	5
360	Clinical Characteristics and Current Practice of Endovascular Revascularization in Aorto-Iliac, Femoropopliteal and Infra-Popliteal Lower Extremity Artery Disease—Insights From the RECCORD Registry. Journal of Clinical Medicine, 2022, 11, 6074.	3.8	8

#	Article	IF	Citations
361	Management of Peripheral Arterial Disease: Lifestyle Modifications and Medical Therapies. Journal of the Society for Cardiovascular Angiography & Interventions, 2022, 1, 100513.	2.3	25
362	Antithrombotic Therapy Following Revascularization for Chronic Limb-Threatening Ischaemia: A European Survey From the ESC Working Group on Aorta and Peripheral Vascular Diseases. European Heart Journal - Cardiovascular Pharmacotherapy, 2023, 9, 201-207.	5.0	15
363	Cost-Effectiveness Analysis of Screening for Peripheral Artery Disease in Patients With Coronary Artery Disease in China: A Markov Model. International Journal of Cardiology, 2023, 371, 420-426.	3.2	0
364	Plasma Extracellular Vesicle Serpin G1 and CD14 Levels Are Associated With Major Adverse Cardiovascular Events and Major Adverse Limb Events in Patients Undergoing Femoral Endarterectomy. European Journal of Vascular and Endovascular Surgery, 2023, 65, 282-290.	3.2	7
365	Comments on the ESC 2022 Guidelines on Cardiovascular Assessment and Management of Patients Undergoing Noncardiac Surgery. Revista Espanola De Cardiologia (English Ed), 2023, 76, 287-293.	1.1	3
366	Endothelial Cell Dysfunction: Implications for the Pathogenesis of Peripheral Artery Disease. Frontiers in Cardiovascular Medicine, 2022, 9, 1054576.	3.2	51
367	Endovascular Repair of a Traumatic Popliteal Artery Injury. Cureus, 2022, 14, e31100.	1.3	4
368	Anticoagulation and Antiplatelet Agents in Peripheral Arterial Interventions. Seminars in Interventional Radiology, 2022, 39, 364-372.	1.1	2
369	Integrating Mechanisms in Thrombotic Peripheral Arterial Disease. Pharmaceuticals, 2022, 15, 1428.	6.1	14
370	Diagnosis and Optimal Medical Treatment of Lower Limb Artery Diseases. Cardiovascular Medicine(Switzerland), 2021, .	0.1	0
371	Socioecological Model-Based Design and Implementation Principles of Lower Limb Preservation Programs as Partners for Limb-Loss Rehabilitation Programs— A Mini-Review. Frontiers in Rehabilitation Sciences, 2022, 3, 983432.	2.7	5
372	Antithrombotische Therapie bei pAVK und Aortenerkrankungen. Aktuelle Kardiologie, 2022, 11, 560-564.	0.0	5
373	Retrospective Multicenter Registry for Endovascular Treatment With Newer Devices in Over 25-Cm Femoropopliteal Artery Disease: A Retrospective Observational Study. Health Science Reports, 2023, 6, e1003.	3.1	4
374	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023. Diabetes Care, 2023, 46, S158-S190.	20.9	464
375	Predicting Arterial Thrombotic Events Following Peripheral Revascularization Using Objective Viscoelastic Data. Journal of the American Heart Association, 2023, 12, e027790.	5.8	28
376	Acetylsalicylic Acid—Primus Inter Pares in Pharmacology. Molecules, 2022, 27, 8412.	5.4	37
377	Immune Checkpoint Inhibitors and the Risk of Major Atherosclerotic Cardiovascular Events in Patients With High-Risk or Advanced Melanoma: A Retrospective Cohort Study. Cardio-Oncology, 2022, 8, 1-8.	5.3	16
378	Gefäßchirurgie bei alten Menschen. Die Chirurgie, 2023, 94, 10-16.	0.7	5

#	Article	IF	Citations
379	Rivaroxaban in Patients With Symptomatic Peripheral Artery Disease After Lower Extremity Bypass Surgery With Venous and Prosthetic Conduits. Journal of Vascular Surgery, 2023, 77, 1107-1118.e2.	3.4	21
380	PAVK bei Diabetikern: Interventionen und Sekundärprophylaxe. Info Diabetologie, 2022, 16, 30-36.	0.1	0
381	Российский консенсус по диагностике и лечению пациентов со стенозом сонных артерий. Russian Journal of Cardiology, 2022, 27, 5284.	1.9	50
382	Dual Pathway Inhibition in Patients With Atherosclerotic Disease: Pharmacodynamic Considerations and Clinical Implications. Expert Review of Clinical Pharmacology, 2023, 16, 27-38.	3.6	18
383	Peripheral Artery Disease (PAD). Contemporary Cardiology, 2023, .	0.0	0
384	Total Events and Net Clinical Benefit of Rivaroxaban and Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease: The COMPASS Trial. American Heart Journal, 2023, 258, 60-68.	3.3	14
385	Secondary Prevention of Antithrombotic Therapy in Patients With Stable Cardiovascular Disease at High Ischemic Risk: A Network Meta-Analysis of Randomized Controlled Trials. Frontiers in Cardiovascular Medicine, 2023, 9, 1040473.	3.2	4
386	Cardiovascular Disease Management in the Context of Global Crisis. International Journal of Environmental Research and Public Health, 2023, 20, 689.	4.2	9
387	Racial and Ethnic Disparities in Clinical Trials and Peripheral Artery Disease. Seminars in Vascular Surgery, 2023, 36, 33-38.	2.8	2
388	Bleeding Risk in Patients With Peripheral Arterial Disease. Life, 2023, 13, 47.	4.3	10
389	Comentarios a la guía ESC 2022 sobre la evaluación cardiovascular y la estrategia de tratamiento de los pacientes que se someten a cirugía no cardiaca. Revista Espanola De Cardiologia, 2023, 76, 287-293.	0.4	0
390	Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association. Circulation, 2023, 147, e93-e621.	24.6	4,839
391	Tradeoffs in Approach to PAD Revascularization: Shared Decision Making in the Spotlight. Journal of the American College of Cardiology, 2023, 81, 371-373.	12.0	1
392	Use of Thromboelastography With Platelet Mapping to Identify Prothrombotic Coagulation Profiles in Patients With History of Cardiac Intervention Undergoing Lower Extremity Revascularization. Journal of the American College of Surgeons, 2023, 236, 495.	2.5	8
393	Community Distress and Risk of Adverse Outcomes After Peripheral Vascular Intervention. Journal of Vascular Surgery, 2023, 78, 166-174.e3.	3.4	11
394	Association of Anticoagulation and Major Adverse Limb Events After Index Peripheral Endovascular Intervention. American Journal of Cardiology, 2023, 192, 124-131.	2.4	9
395	Peripheral Arterial Disease (PAD) – A Challenging Manifestation of Atherosclerosis. Preventive Medicine, 2023, 171, 107489.	3.3	69
396	Endovascular Treatment of an Aneurysmal Vein Graft Twenty-Six Years After Infrainguinal Revascularization. Annals of Vascular Surgery Brief Reports and Innovations, 2023, 3, 100189.	0.3	0

#	Article	IF	Citations
397	The Challenge of Managing Patients With Coronary and Peripheral Arterial Disease - The Ridge Walk Between Bleeding and Ischaemia. International Journal of Cardiology, 2023, 376, 24-25.	3.2	0
398	Arzneiverordnungs-Report 2022. , 2022, .		60
399	Using Genetic Association Data to Guide Drug Discovery and Development: Review of Methods and Applications. American Journal of Human Genetics, 2023, 110, 195-214.	7.2	126
400	Direct Oral Anticoagulants as the First Choice of Anticoagulation for Patients With Peripheral Artery Disease to Prevent Adverse Vascular Events: A Systematic Review and Meta-Analysis. Journal of Cardiovascular Development and Disease, 2023, 10, 65.	2.9	14
401	Chinese Expert Consensus on Antithrombotic Management of High-Risk Elderly Patients With Chronic Coronary Syndrome. Aging Medicine (Milton (N S W)), 2023, 6, 4-24.	3.2	4
402	Atrial Fibrillation in UK South Asian Hospitalized Ischemic Stroke Patients: The BRAINS Study. PLoS ONE, 2023, 18, e0281014.	3.2	2
403	A Multicenter, Randomized, Open-Labelled, Non-Inferiority Trial of Sustained-Release Sarpogrelate Versus Clopidogrel After Femoropopliteal Artery Intervention. Scientific Reports, 2023, 13, 1-10.	5.2	5
404	Guideline-Directed Medical Therapy in PAD: Time to Step on the Gas. JACC: Cardiovascular Interventions, 2023, 16, 344-346.	5.0	1
405	Effect of the Timing of Iliac Vein Stent Implantation on Catheter-Directed Thrombolysis in Acute Lower Extremity Deep Venous Thrombosis Patients With Severe Iliac Vein Stenosis: A Retrospective Study. Phlebology, 2023, 38, 181-189.	1.6	3
406	Prophylactic Efficacy and Safety of Antithrombotic Regimens in Patients With Stable Atherosclerotic Cardiovascular Disease (S-ASCVD): A Bayesian Network Meta-Regression Analysis. American Journal of Cardiovascular Drugs, 2023, 23, 257-267.	3.7	0
407	Prescribing of Low-Dose Rivaroxaban in Patients With Atherosclerotic Cardiovascular Disease in the United Kingdom and the Netherlands. British Journal of Clinical Pharmacology, 2023, 89, 2263-2271.	3.0	0
408	Patient Characteristics in the Recording Courses of Vascular Diseases (Reccord) Registry: Comparison With the Voyager Pad Endovascular Cohort. Journal of Cardiovascular Development and Disease, 2023, 10, 115.	2.9	2
409	Limb Salvage in Octogenarians With Critical Limb Ischemia After Lower Extremity Bypass Surgery. Journal of Vascular Surgery, 2023, 78, 217-222.	3.4	6
410	In Silico Study to Investigate Targeting Ability of Genistein Against Fatty Acid Binding Protein 4 (FABP4) in Peripheral Artery Disease. , 2023, .		0
411	Evidenzbasierte Gefäßchirurgie. Evidenzbasierte Chirurgie, 2022, .	0.0	2
412	A Framework for Perioperative Care for Lower Extremity Vascular Bypasses: A Consensus Statement by the Enhanced Recovery After Surgery (ERAS®) Society and Society for Vascular Surgery. Journal of Vascular Surgery, 2023, 77, 1295-1315.	3.4	50
413	The European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases: An Indispensable Resource in Vascular Care. European Journal of Vascular and Endovascular Surgery, 2023, 65, 621-622.	3.2	9
414	Evidenzbasierte antithrombotische Therapie der peripheren arteriellen Verschlusskrankheit (PAVK). Gefasschirurgie, 2023, 28, 208-215.	0.4	2

#	Article	IF	Citations
415	Surgical Treatment of Acute Arterial Diseases in COVID-19 Patients. Kardiologiya I Serdechno-Sosudistaya Khirurgiya, 2023, 16, 223-229.	0.2	0
416	Peripheral Arterial Disease: A Small and Large Vessel Problem. American Heart Journal Plus, 2023, 28, 100291.	2.1	35
417	Lower-Limb Peripheral Arterial Disease and Amputations in People With Diabetes: Risk Factors, Prognostic Value and Management. Presse Medicale, 2023, 52, 104164.	4.8	18
418	Peripheral Arterial Disease and the Cardiometabolic Syndrome: Assessment and Management. Cardiovascular Endocrinology and Metabolism, 2023, .	1.5	0
419	Current Concepts and Novel Targets for Antiplatelet Therapy. Nature Reviews Cardiology, 2023, 20, 583-599.	62.4	132
420	Editor's Choice – European Society for Vascular Surgery (ESVS) 2023 Clinical Practice Guidelines on Antithrombotic Therapy for Vascular Diseases. European Journal of Vascular and Endovascular Surgery, 2023, 65, 627-689.	3.2	194
421	Outcomes Among Patients With Peripheral Artery Disease in the Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-Term Effectiveness (ADAPTABLE) Study. Vascular Medicine, 2023, 28, 122-130.	2.3	0
422	Antithrombotic Therapy in Peripheral Artery Disease: Current Evidence and Future Directions. Journal of Cardiovascular Development and Disease, 2023, 10, 164.	2.9	21
423	NETs-Induced Thrombosis Impacts on Cardiovascular and Chronic Kidney Disease. Circulation Research, 2023, 132, 933-949.	15.7	101
424	Symptomatic Peripheral Arterial Disease: Aspirin Simply Is Not Enough. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2023, 11, 675.	2.6	0
425	Women Are Not at Higher Risk for Reintervention or Major Amputation After Lower Extremity Atherectomy for Peripheral Artery Disease. Annals of Vascular Surgery, 2023, 95, 95-107.	1.8	6
426	Present and Future Perspectives on the Role of Biomarkers in Atherosclerotic Cardiovascular Disease Risk Stratification. European Cardiology Review, 2022, 18, e13.	2.4	3
427	Endovascular Treatment of Femoro-Popliteal Occlusions With Retrograde Tibial Access After Failure of the Antegrade Approach. Catheterization and Cardiovascular Interventions, 2023, 101, 1108-1119.	2.2	14
428	Optimization of the Pharmacological Therapy in Patients With Poly-Vascular Disease: A Multidisciplinary Approach. World Journal of Cardiology, 2023, 15, 142-153.	2.5	8
429	Ischemia of Lower Limbs in the Activity of a General Practitioner — Family Physician: From Widely Spread to Rare Disorders (Literature Review With Some Results of the Own Clinical Observations). Emergency Medicine, 2023, 19, 21-31.	0.4	2
430	Gene Therapeutic Strategies for Peripheral Artery Disease and New Opportunities Provided by Adeno-Associated Virus Vectors. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 836-851.	7.9	29
431	Optimal Medical Management in Patients Undergoing Peripheral Vascular Interventions for Chronic Limb-Threatening Ischemia Is Associated With Improved Outcomes. Journal of Vascular Surgery, 2023, 78, 490-497.	3.4	10
432	Low Dose Rivaroxaban for the Management of Atherosclerotic Cardiovascular Disease. Journal of Thrombosis and Thrombolysis, 2023, 56, 91-102.	2.2	9

#	Article	IF	Citations
433	Comprehensive Care of Lower-Extremity Wounds. Surgical Clinics of North America, 2023, 103, 745-765.	2.6	7
434	The Ability to Look Beyond: The Treatment of Peripheral Arterial Disease. Journal of Clinical Medicine, 2023, 12, 3073.	3.8	2
435	Oral Factor Xa Inhibitor Underutilization Following Lower Extremity Peripheral Vascular Intervention. Journal of Vascular Surgery, 2023, 78, 498-505.e1.	3.4	8
436	Preventing Lower Limb Graft Thrombosis After Infrainguinal Arterial Bypass Surgery With Antithrombotic Agents (PATENT Study): An International Expert Based Delphi Consensus. Journal of Clinical Medicine, 2023, 12, 3223.	3.8	2
437	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus. Die Diabetologie, 2023, 19, 433-443.	0.1	2
438	Boosting Protection for Patients With Non-Acute Cardiovascular Disease: A Focus on Antithrombotic Regimen (a Consensus Expert Opinion From the Egyptian Society of Cardiology Working Group of Thrombosis and Prevention). Egyptian Heart Journal, 2023, 75, 40.	1.8	1
439	NT-proBNP as a Surrogate for Unknown Heart Failure and Its Predictive Power for Peripheral Artery Disease Outcome and Phenotype. Scientific Reports, 2023, 13, 1-9.	5.2	5
440	Medical Management of Cardiovascular Disease. Surgical Clinics of North America, 2023, 103, 565-575.	2.6	2
441	Baseline Modern Medical Management in the BEST-CLI Trial. Journal of Vascular Surgery, 2023, 78, 711-718.e5.	3.4	34
442	Focus on the Prevention of Acute Limb Ischemia: Centrality of the General Practitioner From the Point of View of the Internist. Journal of Clinical Medicine, 2023, 12, 3652.	3.8	4
443	Clinical Outcomes Based on High Bleeding Risk in Patients With Lower Extremity Peripheral Artery Disease Who Have Undergone Endovascular Therapy. Journal of Endovascular Therapy, 2025, 32, 439-451.	2.1	4
444	Optimal Activated Clotting Time During Peripheral Artery Endovascular Procedures: Cutting the Gordian Knot. Journal of Cardiovascular Surgery, 2023, 64, 240-246.	0.8	4
445	Clinical Use of Direct Oral Anticoagulants and Reversal: Consideration for Vascular Surgeons. Journal of Vascular Diseases, 2023, 2, 230-235.	1.3	1
446	A Case of Symptomatic Supratherapeutic International Normalized Ratio on Rivaroxaban. Cureus, 2023, 15, e40282.	1.3	0
447	Medical Management of Peripheral Artery Disease. Seminars in Interventional Radiology, 2023, 40, 119-128.	1.1	3
448	An Update on Novel Therapies for Treating Patients With Arterial Thrombosis. Expert Review of Hematology, 2023, 16, 593-605.	2.7	6
449	Below-Knee Prosthetic Bypass Is a Viable Option for Limb Salvage in Patients With Extensive Femoropopliteal Occlusive Disease. Vascular Specialist International, 2023, 39, 16.	1.3	6
450	Focus on Prevention: Peripheral Arterial Disease and the Central Role of the Cardiologist. Journal of Clinical Medicine, 2023, 12, 4338.	3.8	7

#	Article	IF	Citations
451	Emergent Management of Diabetic Foot Problems in the Modern Era: Improving Outcomes. Seminars in Vascular Surgery, 2023, 36, 224-233.	2.8	14
452	Nationwide Study in France to Predict One Year Major Bleeding and Validate the OAC3-PAD Score in Patients Undergoing Revascularisation for Lower Extremity Arterial Disease. European Journal of Vascular and Endovascular Surgery, 2023, 66, 213-219.	3.2	15
453	Atherosclerotic Disease: Pathogenesis and Approaches to Management. Medical Clinics of North America, 2023, 107, 793-805.	5.3	55
454	Association of Sex and Cardiovascular Risk Factors With Atherosclerosis Distribution Pattern in Lower Extremity Peripheral Artery Disease. Frontiers in Cardiovascular Medicine, 2023, 10, 1004003.	3.2	4
455	Peripheral Artery Disease: Overview of Diagnosis and Medical Therapy. Medical Clinics of North America, 2023, 107, 807-822.	5.3	14
456	A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice. International Journal of Molecular Sciences, 2023, 24, 11132.	5.9	20
457	Optimal Management of Femoropopliteal Arterial Disease in Patients With Intermittent Claudication. JACC: Cardiovascular Interventions, 2023, 16, 1679-1681.	5.0	3
458	Enhanced Oral Bioavailability of Rivaroxaban-Loaded Microspheres by Optimizing the Polymer and Surfactant Based on Molecular Interaction Mechanisms. Molecular Pharmaceutics, 2023, 20, 4153-4164.	5.2	22
459	Detection, Management, and Prevention of Diabetes-Related Foot Disease in the Australian Context. World Journal of Diabetes, 2023, 14, 942-957.	4.4	1
460	Predicting Outcomes Following Open Revascularization for Aortoiliac Occlusive Disease Using Machine Learning. Journal of Vascular Surgery, 2023, 78, 1449-1460.e7.	3.4	14
461	. Advances in Clinical Medicine, 2023, 13, 11416.	0.1	1
462	Thromboembolische Erkrankungen Aus Angiologischer Sicht. Deutsche Medizinische Wochenschrift, 2023, 148, 890-898.	0.3	1
463	Poor Below Knee Runoff Impacts Femoropopliteal Stent Failure and Fluoropolymer Antithrombotic Effect in Healthy Swine Model. European Journal of Vascular and Endovascular Surgery, 2023, 66, 722-729.	3.2	12
464	Peripheral Artery Disease: Update on Etiology, Pathophysiology, Diagnosis and Treatment. Medicina Clínica, 2023, 161, 344-350.	1.2	71
465	Kardiale, Perioperative Risikobeurteilung. Springer Reference Medizin, 2023, .	0.0	0
466	Editor's Choice – Endovascular Versus Surgical Treatment for All Comer Patients With Prosthetic Bypass Graft Occlusion: The Multicentre ENSUPRO Study. European Journal of Vascular and Endovascular Surgery, 2024, 67, 786-796.	3.2	6
467	Expanding Indications of Nonvitamin K Oral Anticoagulants Beyond Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Review of Emerging Clinical Evidence. Current Problems in Cardiology, 2024, 49, 102017.	4.1	5
468	Type 2 cytokines promote angiogenesis in ischemic muscle via endothelial IL-4Rα signaling. Cell Reports, 2023, 42, 112964.	7.7	21

#	Article	IF	Citations
469	Peripheral Arterial Disease and the Pharmacist's Role in Management. Journal of Clinical Pharmacy and Therapeutics, 2023, .	1.0	0
470	Cardiovascular Effects of Rivaroxaban in Heart Failure Patients With Sinus Rhythm and Coronary Disease With and Without Diabetes: A Retrospective International Cohort Study From COMMANDER-HF. BMJ Open, 2023, 13, e068865.	2.7	2
471	Dual Antiplatelet Therapy or Antiplatelet Plus Anticoagulant Therapy in Patients With Peripheral and Chronic Coronary Artery Disease: An Updated Review. Journal of Clinical Medicine, 2023, 12, 5284.	3.8	8
472	The Indian Consensus Statement for the Management of Lower Extremity Peripheral Artery Disease. Journal of Indian College of Cardiology, 2023, 13, S1.	0.3	12
473	Revascularization for Claudication: Changing the Natural History of a Benign Disease!. Journal of Vascular Surgery, 2024, 79, 159-166.	3.4	24
474	Peripheral Vascular Disease. Primary Care - Clinics in Office Practice, 2024, 51, 83-93.	3.7	12
475	Impact of Factor Xa Inhibition on Coagulation, Platelet Reactivity, and Thrombosis in Patients With Peripheral Artery Disease. Annals of Vascular Surgery, 2023, 97, 211-220.	1.8	8
476	Diabetes- Versus Smoking-Related Thrombo-Inflammation in Peripheral Artery Disease. Cardiovascular Diabetology, 2023, 22, 1-13.	15.7	25
477	Limb Salvage and Survival in Chronic Limb-Threatening Ischemia: The Need for a Fast-Track Team-Based Approach. Journal of Clinical Medicine, 2023, 12, 6081.	3.8	56
478	Unresolved Issues in the Use of Direct Acting Oral Anticoagulants. Expert Review of Cardiovascular Therapy, 2023, 21, 913-921.	2.7	3
479	Non-Coronary Atherosclerotic Arterial Disease: Where Are We Now?. American Journal of Medicine, 2023, 136, 1063-1069.	3.2	0
480	Therapeutic Anticoagulation After Index Peripheral Endovascular Intervention in Patients With Claudication. Journal of Vascular Surgery, 2023, 78, 1461-1470.e2.	3.4	1
481	Risk of Mortality Related to Recurrent Limb Events After Endovascular Revascularization of the Superficial Femoral Artery for Peripheral Artery Disease: The Boston Femoral Artery Endovascular Revascularization Outcomes (Boston FAROUT) Study. American Journal of Cardiology, 2023, 205, 425-430.	2.4	8
482	Limb Preservation for the Vascular Specialist. , 2023, .		2
483	Sex and Racial Disparities in Peripheral Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43, 2099-2114.	7.9	26
484	The Intersocietal IWGDF, ESVS, SVS Guidelines on Peripheral Artery Disease in People With Diabetes Mellitus and a Foot Ulcer. Journal of Vascular Surgery, 2023, 78, 1101-1131.	3.4	93
485	Editor's Choice – The Intersocietal IWGDF, ESVS, SVS Guidelines on Peripheral Artery Disease in People With Diabetes Mellitus and a Foot Ulcer. European Journal of Vascular and Endovascular Surgery, 2023, 66, 454-483.	3.2	74
486	PCSK9-Inhibition to Quench Vascular Injury in Chronic Limb Threatening Ischemia. JACC Basic To Translational Science, 2023, 8, 1078-1080.	4.6	0

#	Article	IF	Citations
487	Pathology, Progression, and Emerging Treatments of Peripheral Artery Disease–Related Limb Ischemia. Clinical Therapeutics, 2023, 45, 1077-1086.	3.4	8
488	Exercise Therapy in the Management of Peripheral Arterial Disease. Mayo Clinic Proceedings Innovations, Quality & Outcomes, 2023, 7, 476-489.	5.4	18
489	Failure-to-Salvage After Femoropopliteal Bypass Surgery Is Associated With Nonmodifiable Risk Factors. Journal of Surgical Research, 2024, 293, 357-363.	1.8	5
490	Editorial: Anticoagulation in Cardiovascular Diseases: Evolving Role, Unmet Needs, and Grey Areas. Frontiers in Cardiovascular Medicine, 2023, 10, 1219033.	3.2	2
491	A Paradigm Shift for Cardiovascular Outcome Evaluation in Diabetes: Major Adverse Cardiovascular Events (MACE) to Major Adverse Vascular Events (MAVE). Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2023, 17, 102875.	4.8	13
492	A Systematic Review of Disparities in the Medical Management of Atherosclerotic Cardiovascular Disease in Females. Seminars in Vascular Surgery, 2023, 36, 517-530.	2.8	4
493	Prosthetic Conduit Use Does Not Adversely Impact Outcomes After Open Repair of Popliteal Artery Aneurysms. Annals of Vascular Surgery, 2024, 98, 124-130.	1.8	5
494	Peripheral Artery Disease: Update on Etiology, Pathophysiology, Diagnosis and Treatment. Medicina Clínica (English Edition), 2023, 161, 344-350.	0.2	1
495	Rivaroxaban Plus Aspirin Versus Aspirin Alone After Endovascular Revascularization for Symptomatic PAD: Insights From VOYAGER PAD. Circulation, 2023, 148, 1919-1928.	24.6	22
496	Editor's Choice – European Society for Vascular Surgery (ESVS) 2024 Clinical Practice Guidelines on the Management of Asymptomatic Lower Limb Peripheral Arterial Disease and Intermittent Claudication☆. European Journal of Vascular and Endovascular Surgery, 2024, 67, 9-96.	3.2	532
497	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus – Gemeinsame Stellungnahme der Deutschen Diabetes Gesellschaft (DDG), der Deutschen Gesellschaft für Angiologie (DGA), der Deutschen Gesellschaft für Interventionelle Radiologie und minimal-invasive Therapie (DeGIR) sowie der Deutschen Gesellschaft für Gefäßchirurgie und Gefäßmedizin (DGG). Diabetologie Und Stoffwechsel, 2023, 18, S370-S380.	0.2	3
498	Perspectives on Lower Extremity Peripheral Artery Disease: A Qualitative Study of Early Diagnosis and Treatment and the Impact of Health Disparities. Population Health Management, 2023, 26, 387-396.	1.5	12
499	Rivaroxaban Plus Aspirin vs. Dual Antiplatelet Therapy in Endovascular Treatment in Peripheral Artery Disease and Analysis of Medication Utilization of Different Lesioned Vascular Regions. Frontiers in Surgery, 2023, 10, 1285553.	2.2	3
500	Peripheral Arterial Disease. , 2023, .		0
501	Preventive Therapies in Peripheral Arterial Disease. Biomedicines, 2023, 11, 3157.	4.9	10
502	Head-to-Head Comparison of 2 Paclitaxel-Coated Balloons for Femoropopliteal Lesions. JACC: Cardiovascular Interventions, 2023, 16, 2900-2914.	5.0	5
503	Efficiency and Safety of Dual Pathway Inhibition for the Prevention of Femoropopliteal Artery Restenosis in Repeated Endovascular Interventions. Journal of Vascular Surgery, 2024, 79, 623-631.e2.	3.4	1
504	Personalized Approaches to Antiplatelet Treatment for Cardiovascular Diseases: An Umbrella Review. Pharmacogenomics and Personalized Medicine, 2023, 16, 973-990.	2.8	16

#	Article	IF	Citations
505	Peripheral Artery Disease: Underappreciated Impact and Residual Cardiovascular Risk Despite Revascularization. Clinical Therapeutics, 2023, 45, 1019-1022.	3.4	25
506	Vascular Protection With Rivaroxaban in the Comprehensive Management of Atrial Fibrillation. Expert Review of Cardiovascular Therapy, 2023, 21, 791-802.	2.7	1
507	Management of Acute Lower Limb Ischemia Without Surgical Revascularization – A Population-Based Study. Vascular and Endovascular Surgery, 2024, 58, 316-325.	0.9	3
508	Antithrombotic Prophylaxis With Rivaroxaban in Patients With Prehospital COVID-19: A Meta-Analysis of Two Placebo-Controlled Trials. Thrombosis and Haemostasis, 2024, 124, 649-655.	4.6	2
509	A New Declaration for Feet's Sake: Halving the Global Diabetic Foot Disease Burden From 2% to 1% With Next Generation Care. Diabetes/Metabolism Research and Reviews, 2024, 40, e3747.	8.4	71
510	Assessment of Clinical and Economic Impact of Rivaroxaban Plus Aspirin vs. Aspirin Alone as a Secondary Prophylaxis in Patients With Chronic and Symptomatic Peripheral Arterial Disease in the United States. Journal of Medical Economics, 2024, 27, 10-15.	3.0	0
511	External Validation of the OAC3-PAD Bleeding Score in a Nationwide Population of Patients Undergoing Invasive Treatment for Peripheral Arterial Disease. European Journal of Vascular and Endovascular Surgery, 2024, 67, 621-629.	3.2	5
512	Comparison of Rivaroxaban-Based Dual Antithrombotic and Antiplatelet Therapies for Symptomatic Patients With Lower-Extremity Peripheral Artery Disease Post-Revascularization: A Retrospective Cohort Study. Therapeutic Advances in Chronic Disease, 2023, 14, 20406223231213262.	3.1	1
513	A Unique Mechanism of Restenosis After Drug-Coated Balloon in Peripheral Artery: Insight From Optical Frequency Domain Imaging. Cardiovascular Revascularization Medicine, 2024, 62, 119-122.	1.6	4
514	Overcoming Challenges to Implementing New Evidence for Low-Dose Anticoagulant Use in Peripheral Artery Disease. Circulation, 2023, 148, 1929-1931.	24.6	1
515	Outcomes of Lower Extremity Peripheral Arterial Interventions in Patients With and Without Chronic Kidney Disease or End-Stage Renal Disease. Journal of Cardiovascular Surgery, 2023, 64, 624-633.	0.8	2
516	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2024. Diabetes Care, 2024, 47, S179-S218.	20.9	547
517	Improving Physical, Physiological, and Psychological Health Outcomes in Patients With Diabetic Foot Ulcers – State of the Art. Clinical, Cosmetic and Investigational Dermatology, 2023, 16, 3547-3560.	2.8	18
518	Platelet Function Testing and Clinical Outcomes in Peripheral Arterial Disease: Systematic Review and Narrative Synthesis. Journal of Vascular Surgery, 2024, 0, 269-278.	3.4	8
519	Dual Antithrombotic Therapy Dose-Dependently Alters Hemostatic Plug Structure and Function. Journal of Thrombosis and Haemostasis, 2024, 22, 1016-1023.	5.0	4
520	Using Machine Learning (XGBoost) to Predict Outcomes Following Infrainguinal Bypass for Peripheral Artery Disease. Annals of Surgery, 2024, 279, 10.1097/SLA.0000000000006181.	6.7	38
521	Kardiale, Perioperative Risikobeurteilung. Springer Reference Medizin, 2023, .	0.0	0
522	Gefäßerkrankungen bei Diabetes mellitus. Die Diabetologie, 2024, 20, 293-302.	0.1	0

#	Article	IF	Citations
523	Association of Immunologic Findings of Atheromatous Plaques With Subsequent Cardiovascular Events in Patients With Peripheral Artery Disease. Scientific Reports, 2024, 14, 1-7.	5.2	6
524	Combined Use of Anticoagulant and Antiplatelet on Outcome After Stroke in Patients With Nonvalvular Atrial Fibrillation and Systemic Atherosclerosis. Scientific Reports, 2024, 14, 1-10.	5.2	18
525	Evidence-Based Therapy in Vascular Surgery. , 2023, .		0
526	Identifying the Highest Risk Vascular Patients: Insights From the XATOA Registry. American Heart Journal, 2024, 269, 191-200.	3.3	11
527	Peripheral Vascular Disease. , 2024, .		3
528	When Direct Oral Anticoagulants Should Not Be Standard Treatment: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 2024, 83, 444-465.	12.0	87
529	Voyaging to Safety: Anticoagulation in Peripheral Artery Disease and Limb Revascularisation. , 2024, .		0
530	Impact of Bempedoic Acid on Total Cardiovascular Events: A Prespecified Analysis of the CLEAR Outcomes Randomized Clinical Trial. JAMA Cardiology, 2024, 9, 245-253.	16.3	44
531	2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation, 2024, 149, e347-e913.	24.6	2,639
532	Incorporating Prior Data in Quantitative Benefit–Risk Assessments: Case Study of a Bayesian Method. Therapeutic Innovation and Regulatory Science, 2024, 58, 415-422.	2.9	0
533	Comparison of Direct Oral Anticoagulants and Warfarin in Chronic Limb-Threatening Ischemia. Journal of Vascular Surgery, 2024, 79, 1466-1472.e1.	3.4	4
534	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (PAVK) bei Menschen mit Diabetes mellitus. Die Diabetologie, 2024, 20, 261-270.	0.1	0
535	Clinical Implications of Diverse Calcification Patterns in Endovascular Therapy for Femoral-Popliteal Arterial Occlusive Disease. Journal of Vascular Surgery, 2024, 80, 188-198.e1.	3.4	12
536	Growth Differentiation Factor-15 and Clinical Outcomes in Lower Extremity Artery Disease. Journal of Atherosclerosis and Thrombosis, 2024, 31, 64515.	3.7	5
537	RIvaroxaban and VAscular Surgery (RIVAS): Insights From a Multicenter, Worldwide Web-Based Survey. International Angiology, 2024, 43, 306-308.	1.8	11
538	Predictors of Amputation-Free Survival and Wound Healing After Infrainguinal Bypass With Alternative Conduits. Journal of Vascular Surgery, 2024, 0, 1447-1456.e2.	3.4	8
539	Editor's Choice – Revascularisation for Peripheral Artery Disease in France: Implications for the Implementation of VOYAGER-PAD. European Journal of Vascular and Endovascular Surgery, 2024, 67, 969-978.	3.2	5
540	Predicting Outcomes Following Lower Extremity Open Revascularization Using Machine Learning. Scientific Reports, 2024, 14, 1-13.	5.2	9

#	Article	IF	Citations
541	How I Treat the Co-Occurrence of Venous and Arterial Thromboembolism: Anticoagulation, Antiplatelet Therapy, or Both?. Blood, 2024, 143, 2351-2362.	10.6	17
542	Référentiel pied diabétique SFD 2024. Medecine Des Maladies Metaboliques, 2024, 18, 174-197.	0.3	3
543	Geriatric Medicine. , 2024, .		67
544	Unplanned Index Limb Revascularization With Rivaroxaban Versus Placebo in Patients With Critical Limb-Threatening Ischemia After Endovascular and Surgical Treatment: Insights From VOYAGER PAD. Circulation, 2024, 149, 635-637.	24.6	2
545	Primary Results of the Brazilian Registry of Atherothrombotic Disease (NEAT). Scientific Reports, 2024, 14, 1-10.	5.2	11
546	Arzneiverordnungs-Report 2023. , 2023, .		36
547	The Pink Tax: Sex and Gender Disparities in Peripheral Artery Disease. US Cardiology Review, 2023, 18, e04.	2.3	12
548	Mind the Gap Between Clinical Trials and Real World Data: Learning From Patients Revascularised for Peripheral Artery Disease in France. European Journal of Vascular and Endovascular Surgery, 2024, 0, 979.	3.2	2
549	Cilostazol for Peripheral Arterial Disease – A Position Paper From the Italian Society for Angiology and Vascular Medicine. Vasa - European Journal of Vascular Medicine, 2024, 53, 109-119.	2.7	9
550	Ticagrelor With or Without Aspirin Following Percutaneous Coronary Intervention in High-Risk Patients With Concomitant Peripheral Artery Disease: A Subgroup Analysis of the TWILIGHT Randomized Clinical Trial. American Heart Journal, 2024, 272, 11-22.	3.3	3
551	A Practical Guide to Understanding and Treating Peripheral Artery Disease. Journal of Cardiovascular Pharmacology, 2024, 83, 565.	2.5	6
552	Analysis of Appropriateness and Safety When Discharging Patients on Triple-Antithrombotic Therapies. American Journal of Health-System Pharmacy, 2024, 81, S144-S151.	1.4	1
553	Comparative Outcomes of Peripheral Vascular Interventions in Patients on Chronic Anticoagulation With Factor Xa Inhibitors and Vitamin K Antagonists. Annals of Vascular Surgery, 2024, 104, 185-195.	1.8	2
554	Optimizing Medical Management and Risk Factors. Surgery, 2024, 42, 293-301.	0.6	1
555	Methods, Design, and Initial Results of an Angiographic Core Lab From VOYAGER-PAD. Vascular Medicine, 2024, 29, 143-152.	2.3	0
556	The Paradox of Direct-Acting Anticoagulants in Peripheral Arterial Disease in Spain. Angiologia, 2024, .	0.1	0
557	Chinese Expert Consensus on Anti-Thrombotic Therapy for Pan-Vascular Diseases (2023 Edition). Cardiology Plus, 2024, 9, 49.	1.7	10
558	From a Spark to a Flame: The Evolution of Diabetic Foot Disease in the Last Two Decades. International Journal of Lower Extremity Wounds, 2024, 25, 316-320.	2.0	12

#	Article	IF	Citations
559	Clinical Practice Recommendations for Antithrombotic Management of Peripheral Artery Disease: An Indian Perspective. Indian Journal of Vascular and Endovascular Surgery, 2024, 11, 4.	0.3	2
560	Diagnosis and Treatment of Ischemia-Producing Coronary Stenoses Improves 5-Year Survival of Patients Undergoing Major Vascular Surgery. Journal of Vascular Surgery, 2024, 80, 240-248.	3.4	11
561	Efficacy and Safety of Combination Therapy With Low-Dose Rivaroxaban in Patients With Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Clinical Medicine, 2024, 13, 2033.	3.8	1
562	A Systematic Review of the Neutrophil to Lymphocyte and Platelet to Lymphocyte Ratios in Patients With Lower Extremity Arterial Disease. Vasa - European Journal of Vascular Medicine, 2024, 53, 155-171.	2.7	7
563	Quantitative Benefit–Risk Evaluation of Rivaroxaban in Patients After Peripheral Arterial Revascularization: The VOYAGER PAD Trial. Journal of the American Heart Association, 2024, 13, e032782.	5.8	11
564	Medical Optimization of Patients With Symptomatic Peripheral Arterial Disease. Annals of Vascular Surgery, 2024, 0, 170-180.	1.8	1
565	Rationale and Design of the Latin-American Registry of Peripheral Interventions: Insights From SOLACI Peripheral. Journal of the Society for Cardiovascular Angiography & Interventions, 2024, 0, 101931.	2.3	2
566	Dual-Pathway Inhibition With Low-Dose Aspirin and Rivaroxaban Versus Aspirin Monotherapy in Patients With Coronary Artery Disease and Peripheral Artery Disease: Systematic Literature Review and Meta-Analysis. European Cardiology Review, 2023, 19, e01.	2.4	15
567	Appropriate Care in Chronic Limb Threatening Ischemia: A Review of Current Evidence and Outcomes. Seminars in Vascular Surgery, 2024, 37, 249-257.	2.8	8
568	Trends in Oral Anticoagulant Use and Individual Expenditures Across the United States From 2014 to 2020. American Journal of Cardiovascular Drugs, 2024, 24, 433-444.	3.7	25
569	Anticoagulation in Patients With Premature Peripheral Artery Disease Undergoing Lower Extremity Revascularization. Annals of Vascular Surgery, 2024, 105, 150-157.	1.8	4
570	Roles of Integrin in Cardiovascular Diseases: From Basic Research to Clinical Implications. International Journal of Molecular Sciences, 2024, 25, 4096.	5.9	25
571	Pedal Medial Arterial Calcification in Diabetic Foot Ulcers: A Significant Risk Factor of Amputation and Mortality. Journal of Diabetes, 2024, 16, e13527.	5.2	15
572	Comprehensive Management of Challenging Recurrent Aortoiliac and Lower Extremity Occlusive Disease With Simultaneous Modified-Covered Endovascular Reconstruction of the Aortic Bifurcation, Inferior Mesenteric Artery Snorkel, and Lower Extremity Bypass. Vascular, 2025, 33, 309-315.	1.1	1
573	Antithrombotische Therapiestrategien in der Atherosklerose. Kardiologie Up2date, 2024, 20, 65-76.	0.0	0
574	Predicting Outcomes Following Lower Extremity Endovascular Revascularization Using Machine Learning. Journal of the American Heart Association, 2024, 13, e033194.	5.8	19
575	Nationwide Study in France to Predict One-Year Major Bleeding and Validate the OAC3-PAD Score in Patients Undergoing Revascularisation for Lower Extremity Arterial Disease. Angiologia, 2024, .	0.1	0
576	Association Between Diabetes Mellitus and Primary Restenosis Following Endovascular Treatment: A Comprehensive Meta-Analysis of Randomized Controlled Trials. Cardiovascular Diabetology, 2024, 23, 1-37.	15.7	24

#	Article	IF	Citations
577	THEMIS: Justice Delayed. Journal of the American College of Cardiology, 2024, 83, 1637-1639.	12.0	0
578	Mastering Endovascular Techniques. , 2024, .		17
579	Analysis of In-Hospital Deaths in Patients With Critical Limb Ischemia Necessitating Invasive Treatments: Based on a Japanese Nationwide Database. Cardiovascular Intervention and Therapeutics, 2024, 39, 448-459.	5.1	3
580	Medical Therapy for Peripheral Artery Disease. Current Cardiology Reports, 2024, 26, 651-659.	4.5	13
581	The Importance of Optimal Medical Therapy in Patients Undergoing Lower Extremity Bypass. Current Opinion in Cardiology, 2024, 39, 10.1097/HCO.0000000000001157.	2.2	2
582	Management and Pharmacological Treatment of Peripheral Arterial Disease. Journal of Pharmacy Practice, 2024, 37, 1337-1345.	1.3	8
583	Low-Dose Rivaroxaban Plus Aspirin in Patients With Peripheral Artery Disease Undergoing Lower Extremity Revascularization With and Without Concomitant Coronary Artery Disease: Insights From VOYAGER PAD. Circulation, 2024, 149, 1536-1539.	24.6	15
584	Polyvascular Disease Is Common in Patients Undergoing Carotid Endarterectomy and Lower Extremity Bypass and Is Associated With Worse Outcomes. Journal of Vascular Surgery, 2024, 80, 1149-1158.e2.	3.4	4
585	Inequities in Atherosclerotic Cardiovascular Disease Prevention. Progress in Cardiovascular Diseases, 2024, 84, 43-50.	9.7	7
586	Prescriber Decision-Making on Antithrombotic Therapy After Endovascular Intervention for Peripheral Artery Disease: A Protocol for a Discrete Choice Experiment. BMJ Open, 2024, 14, e079668.	2.7	0
587	Contemporary Therapy of Femoropopliteal In-Stent Restenosis / Occlusion, 36-Month Follow Up Study. Vascular and Endovascular Surgery, 2024, 58, 693-700.	0.9	4
588	Practice Patterns of Antiplatelet and Anticoagulant Therapy After Fenestrated/Branched Endovascular Aortic Repair. Journal of Vascular Surgery, 2024, 80, 968-978.e3.	3.4	12
589	Patient Factors Influencing Prescription of Antithrombotic Medication After Lower Limb Endovascular Intervention. European Journal of Vascular and Endovascular Surgery, 2024, 0, 510-518.	3.2	5
590	Dual Antithrombotic Therapy Versus Anticoagulant Monotherapy for Major Adverse Limb Events in Patients With Concomitant Lower Extremity Arterial Disease and Atrial Fibrillation: A Propensity Score Weighted Analysis. European Journal of Vascular and Endovascular Surgery, 2024, 68, 498-507.	3.2	5
591	Polyvascular Disease: A Narrative Review of Risk Factors, Clinical Outcomes and Treatment. Current Cardiology Reports, 2024, 26, 505-520.	4.5	15
592	2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Journal of the American College of Cardiology, 2024, 83, 2497-2604.	12.0	309
593	2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2024, 149, e1313-e1410.	24.6	781
594	Following the COMPASS: Antithrombotic Prescription Trends in Patients With Symptomatic Peripheral Arterial Disease Following Revascularization. Annals of Vascular Surgery, 2024, 106, 341-349.	1.8	4

#	Article	IF	Citations
595	DCRM 2.0: Multispecialty Practice Recommendations for the Management of Diabetes, Cardiorenal, and Metabolic Diseases. Metabolism: Clinical and Experimental, 2024, 0, 155931.	16.0	90
596	DVT—DOACDOAC—. The Japanese Journal of Phlebology, 2024, 35, 83-86.	0.3	0
597	COVID-19-Induced Neonatal Acute Aortic Thrombosis. Indian journal of vascular and endovascular surgery IJVES. CInI- case reports, innovations and images, 2024, 2, 30.	0.0	0
598	Lower Extremity Arterial Reconstruction in Patients With Diabetes Mellitus: Principles of Treatment. Contemporary Diabetes, 2024, .	0.0	0
599	Hypertension in Patients With Peripheral Artery Disease: An Updated Literature Review. Cureus, 2024, 16, e62246.	1.3	7
600	Medical Therapy of PAD. , 2024, .		0
601	Current Molecular Understanding of Peripheral Arterial Disease. , 2024, .		0
602	Epidemiology of Peripheral Artery Disease. , 2024, .		0
603	New Horizons in Peripheral Artery Disease. Age and Ageing, 2024, .	6.9	43
604	Efficacy and Safety of Drugs in Residual Cardiovascular Risk: A Systematic Review of the Literature. International Journal of Cardiology Cardiovascular Risk and Prevention, 2024, 22, 200298.	2.7	2
605	Randomized Trial of a Vascular Care Team vs Education for Patients With Peripheral Artery Disease. Journal of the American College of Cardiology, 2024, 83, 2658-2670.	12.0	25
606	Challenges and Opportunities in the Management of Type 2 Diabetes in Patients With Lower Extremity Peripheral Artery Disease: A Tailored Diagnosis and Treatment Review. Cardiovascular Diabetology, 2024, 23, 1-16.	15.7	29
607	Antiplatelet Treatment With Dual Pathway Inhibition: A Pathway of Consistency?. European Cardiology Review, 2024, 19, e11.	2.4	0
608	Use of Direct Oral Anticoagulants in Patients With Peripheral Artery Disease: A Meta-Analysis. American Journal of Cardiology, 2024, 226, 34-35.	2.4	1
609	Rivaroxaban's Vascular Dose for the Neurovascular Clinician. Chinese Neurosurgical Journal, 2024, 10, 1-3.	1.5	0
610	Direct Oral Anticoagulant Treatment for Atherosclerosis-Induced Aortic Mural Thrombus in an Elderly Male With Aspirin Resistance. Cureus, 2024, 16, e62691.	1.3	2
611	Does Benefits of Rivaroxaban as Add-On to Aspirin Apply to Diabetes-Related Cardiovascular Disease? Insights From the COMPASS and VOYAGER PAD Trials. International Journal of Diabetes in Developing Countries, 2024, 44, 768-770.	1.0	0
612	Effect of Peripheral Interventions in Patients With Peripheral Artery Disease Receiving Rivaroxaban and Aspirin: Analyses From the XATOA Registry. European Journal of Vascular and Endovascular Surgery, 2024, 0, 784-795.	3.2	3

#	Article	IF	Citations
613	Rivaroxaban and Aspirin in Drug-Coated Balloon Angioplasty for Femoropopliteal In-Stent Restenosis: A Retrospective Cohort Study. Annals of Vascular Surgery, 2024, 108, 338-345.	1.8	4
614	Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Milvexian With Aspirin And/Or Clopidogrel in Healthy Participants. Scientific Reports, 2024, 14, 1-14.	5.2	6
615	Gefäßerkrankungen bei Diabetes mellitus. Die Kardiologie, 2024, 18, 395-404.	1.4	0
616	Contemporary National Incidence and Outcomes of Acute Limb Ischemia. Annals of Vascular Surgery, 2025, 0, 224-235.	1.8	24
617	2023 Clinical Practice Guidelines for Diabetes Management in Korea: Full Version Recommendation of the Korean Diabetes Association. Diabetes and Metabolism Journal, 2024, 48, 546-708.	6.9	76
618	Medical Clinics of North America—Periprocedural Antithrombotics: Prophylaxis and Interruption. Medical Clinics of North America, 2024, 108, 1017-1037.	5.3	1
619	Antithrombotic Therapy in Patients Undergoing Peripheral Artery Interventions. Interventional Cardiology Clinics, 2024, 13, 553-559.	1.1	1
620	Safety and Efficacy of Combined Coronary and Peripheral Percutaneous Revascularization: A Proof-of-Concept Study. Journal of Clinical Medicine, 2024, 13, 4516.	3.8	1
621	Regulation of Platelet Activation and Coagulation: Current Concepts, Novel Targets, and Therapies. Interventional Cardiology Clinics, 2024, 13, 451-467.	1.1	1
622	Editor's Choice – Major Adverse Limb Events in Patients Undergoing Revascularisation for Lower Limb Peripheral Arterial Disease: A Nationwide Observational Study☆. European Journal of Vascular and Endovascular Surgery, 2024, 68, 737-745.	3.2	30
623	Epidemiology and Burden of Peripheral Artery Disease in People With Type 2 Diabetes: A Systematic Literature Review. Diabetes Therapy, 2024, 15, 1893-1961.	4.4	44
624	The Impact of Revascularization Strategy on Clinical Failure, Hemodynamic Failure and Chronic Limb Threatening Ischemia Symptoms in the BEST-CLI Trial. Journal of Vascular Surgery, 2024, 0, 1755-1765.e4.	3.4	12
625	Acute Brachial Artery Occlusion Following Cisplatin-Based Chemotherapy: Case Report. SAGE Open Medical Case Reports, 2024, 12, 2050313X241269594.	0.8	1
626	High-Dose Drug-Coated Balloon Versus Polymer-Based Drug-Eluting Stent for Femoropopliteal Artery Disease Treatment. Journal of Endovascular Therapy, 2026, 33, 741-748.	2.1	8
627	Antithrombotic Strategies for Patients With Peripheral Artery Disease: JACC Scientific Statement. Journal of the American College of Cardiology, 2024, 84, 936-952.	12.0	24
628	Frailty in Peripheral Artery Disease Patients Undergoing Revascularization: There Is Strength in Antithrombotic Therapy. Journal of the American College of Cardiology, 2024, 84, 812-814.	12.0	0
629	Low-Dose Rivaroxaban Plus Aspirin in Fragile Patients After Lower Extremity Revascularization. Journal of the American College of Cardiology, 2024, 84, 801-811.	12.0	12
630	Early Thrombus Formation Is Required for Eccentric and Heterogeneous Neointimal Hyperplasia Under Disturbed Flow. Journal of Thrombosis and Haemostasis, 2024, 22, 3614-3628.	5.0	9

#	Article	IF	Citations
631	Cilostazol After Endovascular Therapy for Femoropopliteal Peripheral Arterial Disease: A Systematic Review and Meta-Analysis. Journal of Vascular Surgery, 2025, 81, 767-774.e7.	3.4	6
632	Can Rivaroxaban Improve Claudication Symptoms? A Promise Never Made. NEJM Evidence, 2024, 3, EVIDe2400262.	10.7	0
633	2024 ESC Guidelines for the Management of Peripheral Arterial and Aortic Diseases: Developed by the Task Force on the Management of Peripheral Arterial and Aortic Diseases of the European Society of Cardiology (ESC) Endorsed by the European Association for Cardio-Thoracic Surgery (EACTS), the European Reference Network on Rare Multisystemic Vascular Diseases (VASCERN), and the European Society of Vascular Medicine (ESVM). European Heart Journal, 2024, 45, 3538-3700.	14.7	1,197
634	Practical Prescribing: Direct Oral Anticoagulants. BMJ, The, 2024, 386, e079520.	11.6	1
635	Prospective Multi-Center Longitudinal Study to Validate Accuracy of the Global Anatomic Staging System (GLASS) Score in Predicting Major Acute Limb Events in Patients With Chronic Limb Threatening Ischemia Undergoing Endovascular Intervention: The PROMOTE-GLASS Study Protocol. Vascular and Endovascular Surgery, 2025, 59, 29-38.	0.9	3
636	Markers of Optimal Medical Therapy Are Associated With Improved Limb Outcomes After Elective Revascularization for Intermittent Claudication. Journal of Vascular Surgery, 2025, 81, 200-209.e3.	3.4	11
637	Recurrent Cardiovascular and Limb Events in 294,428 Patients With Coronary or Peripheral Artery Disease or Ischemic Stroke on Antiplatelet Monotherapy: The RESRISK Cohort Study. Atherosclerosis, 2024, 398, 118589.	7.0	8
638	The 2024 ACC/AHA/AACVPR/APMA/ABC/SCAI/SVM/SVN/SVS/SIR/VESS Guideline for the Management of Lower Extremity Peripheral Artery Disease: Pertinent Points for the Interventional Radiologist. Journal of Vascular and Interventional Radiology, 2024, 35, 1743-1751.	2.2	6
639	Acute Limb Ischaemia From Stent Thrombosis: Bad Luck or Bad Protoplasm?. EuroIntervention, 2024, 20, e1122-e1123.	4.9	1
640	Trends in Patient Characteristics and Mortality Among Medicare Patients Diagnosed With Peripheral Artery Disease. Vascular Medicine, 2024, 29, 653-663.	2.3	0
641	Updates in Arterial Ulcers. Nursing Clinics of North America, 2025, 60, 57-75.	1.2	1
642	Three-Year Safety and Efficacy of Endovascular Treatment of Common Femoral Artery in 150 PAD Patients. Biomedicines, 2024, 12, 2213.	4.9	9
643	Long-Term Adverse Limb Events After Femoral Artery Endovascular Revascularization: The Boston FAROUT Study. Journal of the Society for Cardiovascular Angiography & Interventions, 2024, 3, 102241.	2.3	3
644	Addressing Knowledge Gaps in Patients With High-Risk Peripheral Artery Disease. Journal of the Society for Cardiovascular Angiography & Interventions, 2024, 3, 102286.	2.3	0
645	Cardiometabolic Diseases—Recent Advance in Antithrombotic and Thrombolytic Therapies. , 2025, .		1
646	Narrative Review of Chronic Total Occlusion Composition to Develop Biomimetic Models of Chronic Limb-Threatening Ischemia to Enhance Revascularization Strategies. JVS-Vascular Insights: An Open Access Publication from the Society for Vascular Surgery, 2024, 2, 100147.	0.9	0
647	Meta-Analysis of Randomised Controlled Trials Comparing Bypass and Endovascular Revascularisation for Peripheral Artery Disease. Vascular and Endovascular Surgery, 2025, 59, 277-287.	0.9	3
648	Management of Antithrombotic Therapy in Patients Undergoing Dental Procedures. Journal of Thrombosis and Haemostasis, 2025, 23, 47-72.	5.0	12

#	Article	IF	Citations
649	Prediction of Health Status in Patients Undergoing Lower Extremity Intervention for Claudication. Annals of Vascular Surgery, 2025, 110, 314-322.	1.8	4
650	Profiling Oxidative Stress Markers and Cardiovascular Complications in Chronic Kidney Disease Patients Supplemented With Vitamin E. Archives of Medical Sciences Atherosclerotic Diseases, 2024, 9, 183-192.	2.0	2
651	Changes in the Landscape of Anticoagulation: A Focus on Direct Oral Anticoagulants. Lancet Haematology,the, 2024, 11, e938-e950.	14.9	43
652	Dual Antiplatelet Therapy Following Branched or Fenestrated Endovascular Aneurysm Repair Might Be the Best Option. European Journal of Vascular and Endovascular Surgery, 2025, 0, 282-283.	3.2	2
653	Treatment of Femoropopliteal Disease: The Quest for the Best?. Journal of Vascular and Interventional Radiology, 2025, 36, 137-138.	2.2	0
654	Impact of Body Mass Index on Mortality, Limb Amputation, and Bleeding in Patients With Lower Extremity Artery Disease Undergoing Endovascular Therapy. Cardiovascular Intervention and Therapeutics, 2025, 40, 1-10.	5.1	6
655	Anticoagulation in General Practice - What Really Matters. MMW Fortschritte Der Medizin, 2024, 166, 58-64.	0.0	0
656	Stroke Prognosis: The Impact of Combined Thrombotic, Lipid, and Inflammatory Markers. Journal of Atherosclerosis and Thrombosis, 2025, 32, 64984.	3.7	7
657	Brazilian Society of Angiology and Vascular Surgery Guidelines on Peripheral Artery Disease. Jornal Vascular Brasileiro, 2024, 23, e20230059.	1.0	11
658	Antithrombotic Therapy in High Bleeding Risk, Part II: Noncardiac Percutaneous Interventions. JACC: Cardiovascular Interventions, 2024, 17, 2325-2336.	5.0	16
659	Antithrombotic Therapy Following Lower Extremity Endovascular Revascularization: The Results of a Survey of Vascular Specialists. JVS-Vascular Insights: An Open Access Publication from the Society for Vascular Surgery, 2024, 2, 100153.	0.9	7
660	Racial and Socioeconomic Health Disparities in Peripheral Artery Disease. Journal of the American Heart Association, 2024, 13, e031446.	5.8	16
661	Guía de práctica clínica sobre detección y manejo de la enfermedad renal diabética: documento de consenso de la Sociedad Española de Nefrología. Nefrologia, 2025, 45, 1-26.	0.6	5
662	Direct Oral Anticoagulants: Quick Primer on When to Use and When to Avoid. Thrombosis and Haemostasis, 2025, 125, 611-617.	4.6	11
663	Detangling Sex-Based Disparities in Acute Limb Ischemia Outcomes—Progress Is Being Made, but We Are Behind the Curve. Journal of Vascular Surgery, 2024, 80, 1804-1805.	3.4	0
664	External Validation of the OAC3-PAD Risk Score After Endovascular Revascularisation. Vasa - European Journal of Vascular Medicine, 2025, 54, 43-49.	2.7	3
665	Impact of Age Differences in Chronic Limb-Threatening Ischemia Outcomes in Octogenarians. Annals of Vascular Surgery, 2025, 111, 212-224.	1.8	4
666	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus. Diabetologie Und Stoffwechsel, 2024, 19, S337-S347.	0.2	0

#	Article	IF	Citations
667	Was ist neu im Management der peripheren arteriellen Verschlusskrankheit und der aortalen Erkrankungen?. Herz, 2025, 50, 25-33.	1.8	0
668	Comparison of Single Antiplatelet Therapy and Dual Antiplatelet Therapy After Endovascular Therapy in Patients With Lower Extremity Artery Disease. Annals of Vascular Diseases, 2024, 17, oa.24-00056.	0.7	3
669	Association Between Anticoagulant Monotherapy and Lower Risk of Major Adverse Limb Events in Patients With Concomitant Lower Extremity Arterial Disease and Atrial Fibrillation Remains Controversial. European Journal of Vascular and Endovascular Surgery, 2025, 0, 849-850.	3.2	0
670	Skin Necrosis. , 2024, .		17
671	Multidisciplinary Management of Chronic Limb Threatening Ischemia. JACC: Case Reports, 2024, 29, 102717.	0.7	1
672	One-Year Clinical Outcomes of Endovascular Revascularization in Patients With Acute Limb Ischemia. Heart and Vessels, 2025, 40, 1-8.	1.8	3
673	Addressing Common Inferential Mistakes When Failing to Reject the Null-Hypothesis. F1000Research, 2024, 13, 1488.	1.1	4
674	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025. Diabetes Care, 2025, 48, S207-S238.	20.9	322
675	Gefäßmedizinische Rehabilitation bei Patienten mit peripher arterieller Verschlusskrankheit (pAVK)Von der spezialisierten Form zur eigenen Fachabteilung. Die Rehabilitation, 2024, 63, 376-388.	0.8	1
676	Unravelling the Cardio-Renal-Metabolic-Foot Connection in People With Diabetes-Related Foot Ulceration: A Narrative Review. Cardiovascular Diabetology, 2024, 23, 1-18.	15.7	37
677	Optimal Medical Therapy in Peripheral Artery Disease. Interventional Cardiology Clinics, 2025, 14, 137-148.	1.1	0
678	Implementing the 2024 ACC/AHA Multisocietal PAD Guidelines Into Clinical Practice: Key Changes From the 2016 Guidelines. Vascular Medicine, 2025, 30, 110-113.	2.3	0
679	The Best Devices for Superficial Femoral Artery, With “Limited” Cases and Vessel Preparations. Cardiovascular Diagnosis and Therapy, 2024, 14, 1003006-1001006.	2.1	0
680	Thrombosis, Translational Medicine, and Biomarker Research: Moving the Needle. Journal of the American Heart Association, 2025, 14, e038782.	5.8	22
681	Drug-Coated Balloons in Autologous Vein Peripheral-Distal Bypass Graft Maintenance: Advancements and Potential Impact. Journal of Endovascular Therapy, 2026, 33, 1405-1418.	2.1	4
682	TEG-Guided Anticoagulation Assessment in Deep Vein Arterialization: A Prospective Analysis. Annals of Vascular Surgery, 2025, 112, 287-297.	1.8	2
683	Heterogeneity in American and European Peripheral Artery Disease Guidelines on Non-Statin Lipid-Lowering Therapy and Rivaroxaban. Thrombosis and Haemostasis, 2025, 125, 821-824.	4.6	2
684	Anticoagulants: From Chance Discovery to Structure-Based Design. Pharmacological Reviews, 2025, 77, 100037.	18.6	5

#	Article	IF	Citations
685	Dual Pathway Inhibition in Patients With Peripheral Artery Disease in Germany. Vasa - European Journal of Vascular Medicine, 2025, 54, 142-149.	2.7	1
686	MicroRNA Profiling in Chronic Limb-Threatening Ischemia Their Role in Arteriogenesis. International Journal of Angiology, 2025, 34, 83-91.	1.1	0
687	Clopidogrel Combined With Rivaroxaban in Peripheral Artery Disease After Revascularization. Frontiers in Pharmacology, 2025, 15, 1485380.	5.3	2
688	Vascular Quality Initiative Assessment of Compliance With Society for Vascular Surgery Practice Guidelines for the Endovascular Management of Claudication. Journal of Vascular Surgery, 2025, 81, 1155-1163.	3.4	6
689	Impact of Antithrombotic Therapy on Thrombotic and Bleeding Complications After Elective Endovascular Repair of Abdominal Aortic Aneurysms. CardioVascular and Interventional Radiology, 2025, 48, 157-166.	2.3	4
690	Reply: Where the Definition of Fragility Came From and Where It Will Go. Journal of the American College of Cardiology, 2025, 85, e45-e46.	12.0	0
691	Short-Term Outcomes of Dual Versus Single Antiplatelet Therapy Following Popliteal and Infrapopliteal Endovascular Therapy: Data From Dutch Chronic Lower Limb-Threatening Ischemia Registry (THRILLER). Journal of Endovascular Therapy, 2026, 33, 1513-1521.	2.1	0
692	Femoropopliteal Interventions for Peripheral Artery Disease: A Review of Current Evidence and Future Directions. Interventional Cardiology Clinics, 2025, 14, 243-256.	1.1	3
693	Acute Limb Ischemia Interventions. Interventional Cardiology Clinics, 2025, 14, 273-282.	1.1	1
694	Chronic Limb-Threatening Ischemia: A Comprehensive Review Paper. Interventional Cardiology Clinics, 2025, 14, 257-272.	1.1	8
695	Post-Walking Exercise Skeletal Muscle Perfusion and Energetics in Patients With Symptomatic Lower Extremity Peripheral Artery Disease. Journal of Nuclear Cardiology, 2025, 46, 102143.	1.8	5
696	Comparison of the Risk Scoring Systems in Long Term Restenosis Due to Percutaneous Interventions to the Superficial Femoral Artery. Vasa - European Journal of Vascular Medicine, 2025, 54, 184-191.	2.7	4
697	Platelet Activation in Patients With Peripheral Artery Disease From 43 Sites: Assessment of Samples Transported by Overnight Mail. JVS-Vascular Insights: An Open Access Publication from the Society for Vascular Surgery, 2025, 0, 100197.	0.9	0
698	Unmet Needs and Opportunities for Australian Innovation and Clinical Research to Improve Quality of Life and Outcomes in Patients With Peripheral Artery Disease. Heart Lung and Circulation, 2025, 34, 225-234.	2.2	2
699	Rivaroxaban to Reduce the Risk of Major Cardiovascular Events in Patients With Chronic Coronary Artery Disease or Peripheral Artery Disease: A Narrative Review. Expert Opinion on Drug Safety, 2025, 24, 261-271.	3.2	7
700	2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation, 2025, 151, e41-e660.	24.6	1,273
701	IV. The Journal of the Japanese Society of Internal Medicine, 2024, 113, 211-218.	0.0	0
702	Outcomes of SUPERA™ Stent Used for the Treatment of De Novo or Restenotic Superficial Femoral Artery or Complex Femoropopliteal Artery Lesions in Indian Patients. Indian Journal of Vascular and Endovascular Surgery, 2025, 12, 4.	0.3	1

#	Article	IF	Citations
703	Chronic Kidney Disease and Risk of Mortality and Major Adverse Limb Events After Femoral Artery Endovascular Revascularization for Peripheral Artery Disease: The Boston Femoral Artery Endovascular Revascularization Outcomes (Boston FAROUT) Study. Catheterization and Cardiovascular Interventions, 2025, 105, 1214-1221.	2.2	4
704	Lower Extremity Arterial Disease Perspective: IUA Consensus Document on "LEAD Management". Part 2. International Angiology, 2025, 44, 61-70.	1.8	1
705	Endovaskuläre Therapie der aortoiliakalen Verschlusskrankheit. Die Innere Medizin, 2025, 66, 249-257.	0.7	1
706	Periphere Arterielle Verschlusskrankheit. Allgemein- Und Viszeralchirurgie Up2date, 2025, 19, 29-52.	0.0	0
707	Cumulative Impact of Procedural and Anatomical Factors on In-Hospital Bleeding Complications in Endovascular Therapy for Lower-Extremity Artery Disease: A Nationwide Registry Study in Japan. Vascular Medicine, 2025, 30, 155-161.	2.3	1
708	Revaskularisation und Amputationsrisiko bei pAVK und Diabetes mellitus. Gefäßmedizin Scan - Zeitschrift Für Angiologie Gefäßchirurgie Diagnostische Und Interventionelle Radiologie, 2025, 12, 43-53.	0.0	0
709	Cost-Effectiveness and Budget Impact Analysis of Rivaroxaban With or Without Aspirin Compared to Aspirin Alone in Patients With Coronary and Peripheral Artery Diseases in Iran. BMC Health Services Research, 2025, 25, 1-12.	3.8	2
710	Current Insights Into Drug-Coated Balloons for Peripheral Arterial Disease. Expert Opinion on Drug Delivery, 2025, 22, 629-637.	6.1	2
711	Prevalence of Extracranial Carotid Artery Disease in Symptomatic Peripheral Artery Disease and Implications for Long-Term Outcome. Annals of Medicine, 2025, 57, 2478313.	5.0	1
712	Role of Dual Pathway Inhibition in Secondary Prevention of Coronary Artery Disease. Cureus, 2025, 17, e80504.	1.3	0
713	Popliteal Artery Entrapment Syndrome in a 20-Year-Old Man. Cmaj, 2025, 197, E266-E270.	1.8	2
714	External Validity of Randomized Clinical Trials in Vascular Surgery: Systematic Review of Demographic Factors of Patients Recruited to Randomized Clinical Trials With Comparison to the National Vascular Registry. BJS Open, 2025, .	4.3	6
715	Early Risk of Major Adverse Limb Events Following Lower Extremity Revascularization in the VOYAGER-PAD Trial. JACC: Cardiovascular Interventions, 2025, 18, 1211-1213.	5.0	0
716	Variations in Antithrombotic Prescriptions and Evaluation of Extended Clopidogrel Therapy After Lower Extremity Revascularization for Peripheral Artery Disease. Journal of Vascular Surgery, 2025, 82, 581-590.e2.	3.4	1
717	TwPAD Registry: A Prospective, Multicenter Registry of Chronic Peripheral Arterial Disease Involving Lower Limbs in Taiwan. Journal of the Chinese Medical Association, 2025, 88, 389.	2.2	0
718	Artificial Human Blood Vessels for Tissue Engineering. , 2025, 7, 1626-1645.		16
719	Antiplatelet Agents in Peripheral Arterial Disease: A Review. Cardiology in Review, 2025, .	1.7	0
720	Semaglutide and Walking Capacity in People With Symptomatic Peripheral Artery Disease and Type 2 Diabetes (STRIDE): A Phase 3b, Double-Blind, Randomised, Placebo-Controlled Trial. Lancet, The, 2025, 405, 1580-1593.	96.9	194

#	Article	IF	Citations
721	Impact of Peripheral Arterial Disease on Clinical Outcomes of Patients Undergoing Complex vs Noncomplex Percutaneous Coronary Intervention. American Journal of Cardiology, 2025, 247, 76-83.	2.4	4
722	Association Between Medial Calcification and Chronic Thrombus: An Optical Frequency Domain Imaging Study. Catheterization and Cardiovascular Interventions, 2025, 106, 109-119.	2.2	3
723	Validation of High Ischemic and Bleeding Risk Criteria of European Guidelines in Peripheral Arterial Disease. JACC Asia, 2025, 5, 744-754.	3.7	4
724	Perioperative Antithrombotic Strategies in Vascular Surgery: A Survey in Germany. Health Science Reports, 2025, 8, e70732.	3.1	3
725	Textbook Outcomes After Revascularization for Chronic Limb-Threatening Ischemia Remain Rare. Journal of Vascular Surgery, 2025, 82, 536-548.e5.	3.4	1
726	Antithrombotic Agents. , 2025, .		0
727	Suboptimal Use of Cardiovascular Risk Modification Therapies Among Patients Undergoing Vascular Surgery Admitted With Chronic Limb-Threatening Ischemia. JVS-Vascular Insights: An Open Access Publication from the Society for Vascular Surgery, 2025, 3, 100218.	0.9	0
728	Anticoagulation Does Not Improve Limb Outcomes After Lower Extremity Cryopreserved Vein Bypass. Journal of Vascular Surgery, 2025, 82, 998-1006.e2.	3.4	0
729	Peripheral Arterial Disease. Surgery, 2025, 43, 299-305.	0.6	2
730	Clinical Practice Guideline for Detection and Management of Diabetic Kidney Disease: A Consensus Report by the Spanish Society of Nephrology. Nefrologia, 2025, 45, 1-26.	1.3	6
731	Optimal Medical Therapy Is Associated With Improved Limb Outcomes in PAD Patients: A BEST-CLI Substudy. Journal of the American College of Cardiology, 2025, 85, 1568-1572.	12.0	3
732	Long-Term Antithrombotic Therapy in Patients With Chronic Coronary Syndrome: An Updated Review of Current Evidence. Clinical Therapeutics, 2025, 47, 511-518.	3.4	4
733	Dual Antiplatelet Therapy After Iliac Artery Stenting Improves Limb Salvage and Freedom From Major Adverse Limb Events Compared to Single Antiplatelet Therapy. Annals of Vascular Surgery, 2025, 118, 83-97.	1.8	1
734	Challenges of Anticoagulation in Patients With Systemic Lupus Erythematosus. Expert Opinion on Pharmacotherapy, 2025, 26, 849-862.	3.5	1
735	Association Between S100A12 and Risk of Peripheral Arterial Disease in Patients With Dyslipidemia: A Cross-Sectional Study. BMC Cardiovascular Disorders, 2025, 25, 1-10.	3.3	2
736	Arzneiverordnungs-Report 2024. , 2025, .		17
737	A Systematic Review Supporting the Society for Vascular Surgery Guideline Update on the Management of Intermittent Claudication. Journal of Vascular Surgery, 2025, 82, 688-697.	3.4	4
738	Research Priorities for Peripheral Artery Disease: A Statement From the Society for Vascular Medicine. Vascular Medicine, 2025, 30, 367-383.	2.3	9

#	Article	IF	Citations
739	Prescription of Aspirin Plus Low-Dose Rivaroxaban in Patients With Peripheral Artery Disease After Lower-Extremity Revascularization. Vascular Medicine, 2025, 30, 318-320.	2.3	0
740	Society for Vascular Surgery Clinical Practice Guideline on the Management of Intermittent Claudication: Focused Update. Journal of Vascular Surgery, 2025, 82, 303-326.e11.	3.4	28
741	Peripheral Arterial Disease Prevalence Among Sepsis Hospitalizations and Associated Outcomes. Journal of Vascular Surgery, 2025, 82, 1383-1391.e7.	3.4	3
742	Syndrome de l'artère poplitée piégée chez un homme de 20 ans. Cmaj, 2025, 197, E514-E518.	1.8	0
743	Preserving Trial Endpoint Specificity and Cause of Death Attribution in Cardiovascular Trials: Insights From MARINER. JACC: Advances, 2025, 4, 101763.	3.2	0
744	Outcomes of Different Regimens of Rivaroxaban and Aspirin in Cardiovascular Diseases: A Network Meta-Analysis. Journal of Clinical Medicine, 2025, 14, 3437.	3.8	0
745	The Critical Role of Platelets in Venous Thromboembolism: Pathogenesis, Clinical Status, and Emerging Therapeutic Strategies. Blood Reviews, 2025, 74, 101302.	7.6	19
746	Antithrombotic Treatment Following Revascularization for Chronic Limb-Threatening Ischaemia: A Scientific Statement of the European Society of Cardiology Working Group on Aorta and Peripheral Vascular Diseases and the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European Heart Journal, 2025, 46, 2742-2759.	14.7	6
747	Potential Drug Targets for Peripheral Artery Disease Identified Through Mendelian Randomization Analysis. Thrombosis Journal, 2025, 23, 1-10.	2.9	2
748	Antiplatelet and Anticoagulation Therapy for Peripheral Arterial Disease: Risks Versus Benefits. Cardiology in Review, 2025, .	1.7	1
749	Expert Recommendations on Antithrombotic Management of Peripheral Artery Disease: Perspectives From Indian Interventional Radiologists. Journal of Clinical Interventional Radiology ISVIR, 2025, 09, 108-120.	0.3	0
750	Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus. Die Diabetologie, 2025, 21, 478-487.	0.1	0
751	Aspirin Plus Rivaroxaban vs Aspirin Alone: Improvement of Claudication, Limb Pain and Ankle-Brachial Index in Diabetic Peripheral Arterial Disease (PAD) Before Revascularization: A Clinical Randomized Trial. International Cardiovascular Research Journal, 2025, 19, e154736.	0.4	1
752	Antithrombotische Therapie Bei Polyvaskulärer Atherosklerose. Deutsche Medizinische Wochenschrift, 2025, 150, 741-746.	0.3	0
753	In-Hospital Risk Factors for Reintervention and Amputation in Femoral Arterial Trauma. Journal of Surgical Research, 2025, 311, 280-286.	1.8	1
754	Gefäßmedizinische Rehabilitation bei Patienten mit peripher arterieller Verschlusskrankheit (pAVK). Physikalische Medizin Rehabilitationsmedizin Kurortmedizin, 2025, 35, 178-191.	0.4	1
755	Inpatient Outcomes for Patients With Peripheral Artery Disease Hospitalized for Acute Myocardial Infarction. Journal of the American Heart Association, 2025, 14, e040526.	5.8	7
756	Oral Anticoagulant Management for Peripheral Vascular Disease. Advances in Surgery, 2025, 59, 161-199.	2.1	0

#	Article	IF	Citations
757	Efficacy and Safety of Low-Dose Rivaroxaban in High-Ischemic-Risk Patients With Chronic Coronary Syndrome: Rationale and Design of the DUTCH CCS Registry. Journal of Clinical Medicine, 2025, 14, 4401.	3.8	0
758	Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial. Circulation, 2025, 152, 290-296.	24.6	19
759	Twenty-Four-Month Outcomes of Heparin-Bonded Covered Stents and Drug-Coated Balloon Angioplasty in Femoropopliteal Artery Occlusion. Journal of the American Heart Association, 2025, 14, e039384.	5.8	2
760	Systematic Review of the Use of Oral Anticoagulants in Patients With Peripheral Arterial Disease. Future Cardiology, 2025, 21, 711-723.	1.2	2
761	Selecting Oral Antithrombotic Therapies in Peripheral Arterial Disease: A Guide for Practitioners. American Journal of Health-System Pharmacy, 2025, 82, e868-e877.	1.4	1
762	Peripheral Artery Disease and Antithrombotic Management: A Global Perspective on Efficacy, Safety, and Access. Cardiology in Review, 2025, .	1.7	1
763	Comprehensive Insights Into Peripheral Artery Disease: An Overview From the Working Groups of Pathogenesis of Atherosclerosis and Thrombosis of the Italian Society of Cardiology. Journal of Cardiovascular Medicine, 2025, 26, 325.	2.3	3
764	Management of Peripheral Artery Disease. JAMA - Journal of the American Medical Association, 2025, 334, 444-445.	37.0	14
765	2025 Clinical Practice Guidelines for Diabetes Management in Korea: Recommendation of the Korean Diabetes Association. Diabetes and Metabolism Journal, 2025, 49, 582-783.	6.9	53
766	Efficient Statistical Analysis of Trial Designs: Win Ratio and Related Approaches for Composite Outcomes. Perioperative Medicine (London, England), 2025, 14, 70.	2.9	8
767	Evolving Trends and Health Disparities in Peripheral Artery Disease in the United States (1999–2024). Cardiology in Review, 2025, .	1.7	1
768	Prognostic Value of Lipoprotein(a) for Cardiovascular Events After Lower Limb Revascularization in Diabetic Patients With Chronic Limb-Threatening Ischemia. Cardiovascular Diabetology, 2025, 24, 1-16.	15.7	3
769	Management of Claudication in Older Adults and the Role of Exercise Therapy. Seminars in Vascular Surgery, 2025, 38, 271-280.	2.8	1
770	Platelet RNA-Seq Reveals Genes Associated With Carotid Intima-Media Thickness: A Cross-Sectional Study. TH Open, 2025, 09, a26616472.	1.8	0
771	Predicting Outcomes Following Endovascular Aortoiliac Revascularization Using Machine Learning. Npj Digital Medicine, 2025, 8, 475.	20.4	5
772	Early Economic Evaluation of Single Versus Dual Antiplatelet Therapy After Endovascular Revascularization for Peripheral Artery Disease. Annals of Vascular Surgery, 2026, 122, 298-308.	1.8	0
773	Long-Term Effects of Statin and Anticoagulant Therapy on Restenosis After Drug-Coated Balloon Angioplasty for Femoropopliteal Artery Disease: Results From the POPCORN Registry. Cardiovascular Intervention and Therapeutics, 2025, 40, 881-889.	5.1	2
774	Novel Interventions to Improve Adherence to Guideline-Directed Medical Therapy in Claudicants. Journal of Clinical Medicine, 2025, 14, 5309.	3.8	0

#	Article	IF	Citations
775	Antithrombotic Therapy for Lower Limb Peripheral Arterial Disease: A Deep Dive Into Guideline Quality and Recommendation Diversity. Thrombosis Research, 2025, 253, 109414.	2.9	1
776	Dual Pathway Inhibition Versus Antiplatelet Therapy for "Symptomatic" Lower-Extremities Peripheral Artery Disease in Diabetes Mellitus: A Systematic Review and a Meta-Analysis of Randomized Controlled Trials for the Development of the Italian Guidelines for the Treatment of Diabetic Foot Syndrome. Acta Diabetologica, 2026, 63, 1-13.	3.8	0
777	Neonatal Spontaneous Abdominal Aortic Thrombosis Associated With Hypernatremic Dehydration and Acute Renal Failure: A Case Series. Clinical Case Reports (discontinued), 2025, 13, e70736.	0.8	0
778	A Contemporary Paradigm for Value-Based Medicine in Peripheral Artery Disease. Journal of Vascular Surgery, 2025, 82, 2264-2273.	3.4	4
779	Duplex Ultrasound After Endo Revascularisation (DUSTER): Protocol for a Randomised Controlled Feasibility Trial. BMJ Open, 2025, 15, e101137.	2.7	1
780	Systematic Review and Network Meta-Analysis of the Efficacy and Safety of Antithrombotic Options Following Open Surgical Revascularization for Peripheral Arterial Disease. Annals of Vascular Surgery, 2025, 121, 456-468.	1.8	0
781	The Link Between Venous Thromboembolism and Atherothrombosis: Epidemiology, Pathophysiology, and Implications for Clinical Care. European Heart Journal: Acute Cardiovascular Care, 2026, 14, 756-768.	4.0	4
782	DGK-Kommentar zu den Leitlinien der ESC (2024) zur Behandlung der peripheren arteriellen und aortalen Erkrankungen. Die Kardiologie, 2025, 19, 366-378.	1.4	0
783	Risk Factor Management Over Two Decades in Hospitalised Patients With Chronic Limb-Threatening Ischaemia With and Without Diabetes Mellitus. Therapeutic Advances in Endocrinology and Metabolism, 2025, 16, 20420188251362729.	7.9	3
784	Effectiveness and Safety of Rivaroxaban vs. Apixaban in Patients With Atrial Fibrillation and Peripheral Artery Disease. European Heart Journal - Cardiovascular Pharmacotherapy, 2025, 11, 664-673.	5.0	4
785	Paclitaxel-Coated Versus Uncoated Devices for Infrainguinal Endovascular Revascularisation in Chronic Limb-Threatening Ischaemia (SWEDEPAD 1): A Multicentre, Participant-Masked, Registry-Based, Randomised Controlled Trial. Lancet, The, 2025, 406, 1103-1114.	96.9	47
786	Paclitaxel-Coated Versus Uncoated Devices for Infrainguinal Endovascular Revascularisation in Patients With Intermittent Claudication (SWEDEPAD 2): A Multicentre, Participant-Masked, Registry-Based, Randomised Controlled Trial. Lancet, The, 2025, 406, 1115-1127.	96.9	62
787	Toward Better Risk Stratification After Iliofemoral Endovascular Therapy in Lower Extremity Artery Disease. JACC Asia, 2025, 5, 1196-1198.	3.7	0
788	Management of Dual Antiplatelet Therapy Following Covered Femoropopliteal Stenting – Why Size Matters. Vasa - European Journal of Vascular Medicine, 2026, 55, 229-238.	2.7	4
789	Risk Factors for Myocardial Infarction in Patients With Peripheral Artery Disease. International Journal of Cardiology, 2026, 442, 133898.	3.2	1
790	Blombäck's Essential Guide to Blood Coagulation. , 2025, .		2
791	Peripheral Artery Disease. Nature Reviews Disease Primers, 2025, 11, 68.	81.2	41
792	Klinische Angiologie. Springer Reference Medizin, 2025, .	0.0	0

#	Article	IF	Citations
793	MACE and MALE Outcome With Rivaroxaban Following Endovascular Peripheral Arterial Intervention in Diabetes: A Real-World Study. International Journal of Diabetes in Developing Countries, 2026, 46, 1-6.	1.0	0
794	Endovascular Treatment for Calcified Femoropopliteal Peripheral Artery Disease and Risk Factor Identification: Two Year Outcomes of the Evolusion Study. European Journal of Vascular and Endovascular Surgery, 2026, 0, 647-658.	3.2	8
795	Platelets in Peripheral Arterial Disease. , 2025, .		0
796	Antiplatelet Therapy for Peripheral Arterial Disease. , 2025, .		0
797	Endovenous Laser Ablation of Insufficient Superficial Veins in Patients After Deep Vein Thrombosis Recanalisation. Cardiovascular Therapeutics, 2025, 2025, 8458282.	3.0	0
798	Baseline and Longitudinal Patterns of Non-HDL-C to HDL-C Ratio (NHHR) and Major Adverse Cardiovascular Events in Peripheral Artery Disease. Scientific Reports, 2025, 15, 35993.	5.2	2
799	Prevalence, Determinants, and Prognostic Impact of Polyvascular Disease in Patients Hospitalised for Atherosclerosis in Slovenia: A Nationwide, Retrospective Cohort Study. EClinicalMedicine, 2025, 89, 103542.	13.5	0
800	Association Between Smoking and Thromboelastography With Platelet Mapping Parameters in Peripheral Artery Disease Patients. Journal of Surgical Research, 2025, 315, 647-658.	1.8	1
801	Optimizing Selection of P2Y12 Inhibiting Therapy: Clopidogrel, Prasugrel or Ticagrelor. Expert Opinion on Pharmacotherapy, 2025, 26, 1565-1581.	3.5	3
802	Rivaroxaban in Peripheral Artery Disease After Revascularization: Worst Events and Net Outcomes in VOYAGER PAD. Journal of the American Heart Association, 2025, 14, e039752.	5.8	2
803	Beyond First Events: A Closer Look at VOYAGER PAD. Journal of the American Heart Association, 2025, 14, e044370.	5.8	0
804	Enrollment of Historically Underrepresented Groups in Peripheral Arterial Disease Trials: A Systematic Review. Journal of the Society for Cardiovascular Angiography & Interventions, 2026, 0, 103620.	2.3	0
805	Rivaroxaban in Chinese Children With Giant Coronary Artery Aneurysms After Kawasaki Disease. Research and Practice in Thrombosis and Haemostasis, 2025, 9, 103211.	3.3	1
806	PCSK9 Predicts Adverse Limb Outcomes After Endovascular Revascularization in Diabetic Chronic Limb-Threatening Ischemia. Thrombosis and Haemostasis, 2026, 126, 846-855.	4.6	1
807	Types and Rates of Major Adverse Cardiovascular Events in Antithrombotic Trials: A Systematic Review and Meta-Analysis. Canadian Journal of Cardiology, 2025, 0, 2629-2643.	3.8	3
808	Impact of GLP-1 Receptor Agonists on Cardiovascular Outcomes in Patients With Peripheral Artery Disease Without Diabetes: A Propensity Score-Matched Analysis. Journal of Investigative Medicine, 2026, 74, 641-653.	1.9	4
809	Differences Between Published Guidelines and Consensus Statements on the Management of Claudication: Society for Vascular Surgery, American College of Cardiology/American Heart Association, and European Society for Vascular Surgery. , 2025, .		0
810	Behavioral and Mental Health Considerations for Patients Experiencing Vasculogenic Claudication. , 2025, .		0

#	Article	IF	Citations
811	Risks of Revascularization: The So-Called Treatment Trap. , 2025, .		0
812	Revascularization: Common Femoral and Profunda Femoris Arteries—Evidence, Techniques, and Patient Selection. , 2025, .		0
813	Risk Factors for Claudication and Management to Modify Them. , 2025, .		0
814	Pharmacologic Therapy to Improve Functional and Limb Outcomes. , 2025, .		0
815	Adjunct Medical Therapy and Its Impact on Survival and Reintervention Rates in Patients With Common Femoral Artery Disease Undergoing Endovascular Revascularization or Open Repair. Vasa - European Journal of Vascular Medicine, 2026, 55, 281-290.	2.7	0
816	Contemporary Chronic Limb-Threatening Ischemia Care in the United States-Part 2: Designing Clinical Device Trials. Journal of the Society for Cardiovascular Angiography & Interventions, 2025, 4, 103934.	2.3	0
817	Race and Sex Interplay in Female African American Patients With Peripheral Arterial Disease of the Lower Extremities Undergoing Arterial Revascularization. Annals of Vascular Surgery, 2026, 123, 585-592.	1.8	1
818	Practical Guidelines for the Prevention and Management of Diabetic Foot Disease in China. Burns and Trauma, 2025, 13, tkaf064.	10.2	10
819	Safety and Optimal Use of Direct Oral Anticoagulant Therapy. Expert Opinion on Drug Safety, 2026, 25, 1011-1030.	3.2	1
820	Cardiovascular Therapeutics at the Crossroads: Pharmacological, Genetic, and Digital Frontiers. Pharmaceuticals, 2025, 18, 1703.	6.1	2
821	Aspirin or P2Y12 Inhibitor Monotherapy in Atherosclerotic Cardiovascular Disease?. European Heart Journal, 2026, 47, 558-573.	14.7	22
822	Mechanical Thrombectomy Using Indigo System for the Treatment of Acute Lower Limb Venous Bypass Occlusion. Journal of Endovascular Therapy, 2025, .	2.1	3
823	Contemporary Results of Intra-Arterial Thrombolysis for Acute and Acute-on-Chronic Lower Limb Ischemia. Annals of Vascular Surgery, 2026, 123, 684-692.	1.8	3
824	Venous Thromboembolism in Patients Receiving Rivaroxaban Plus Aspirin or Standard Treatment After Lower Limb Revascularization-Rationale and Design of the RESOLUTION Trial. Annals of Vascular Surgery, 2026, 124, 22-27.	1.8	0
825	Cardiovascular Disease and Risk Management. , 2025, .		0
826	Revaskularisation und Amputationsrisiko bei pAVK und Diabetes mellitus. Diabetes Aktuell, 2025, 23, 322-331.	0.1	0
827	Prospective Randomized Clinical Trial Comparing Paclitaxel-Coated Balloon Versus Conventional Balloon Angioplasty in Treating Below the Knee Arterial Lesions in Chronic Limb Threatening Ischemia: The CRURAL DEB Study. Journal of Endovascular Therapy, 2025, .	2.1	1
828	Endothelial CEPT1 Promotes Angiogenesis Through PPARα and VEGF-A Signaling. Arteriosclerosis, Thrombosis, and Vascular Biology, 2026, 46, 195-209.	7.9	3

#	Article	IF	Citations
829	Safety and Efficacy of Anticoagulant Administration in People With Atrial Fibrillation and Advanced Chronic Kidney Disease. Expert Opinion on Drug Safety, 2026, 25, 453-473.	3.2	2
830	The Role of Rivaroxaban in the Management of Coronary Artery Disease: An Overview of Five Landmark Clinical Trials. Naunyn-Schmiedeberg's Archives of Pharmacology, 2026, 399, 1-11.	4.7	0
831	Haemorrhagic Safety Update of CLEAR-PATH: 30 Day and 12 Month Antiplatelet Therapy After Peripheral Angioplasty. EJVES Vascular Forum, 2026, 65, 32-39.	1.0	1
832	Management of Acute Infrainguinal Graft Occlusion: Surgical and Endovascular Approaches in Contemporary Practice. Journal of Personalized Medicine, 2025, 15, 568.	3.9	1
833	The Healing Flow: Assessing Patient Outcomes Post-Peripheral Artery Repair. Research Journal of Life Sciences Bioinformatics Pharmaceutical and Chemical Sciences, 2025, .	0.0	0
834	Angioscopy-Guided Excimer Laser Atherectomy in Femoropopliteal In-Stent Occlusions. Circulation Reports, 2026, 8, CR-25-0199.	1.9	0
835	2025JCS/Jsvs . Journal of the Nihon University Medical Association, 2025, 84, 197-200.	0.1	0
836	„S3-Leitlinie zur Diagnostik, Therapie und Nachsorge der peripheren arteriellen Verschlusskrankheit“. Zeitschrift Fur Gerontologie Und Geriatrie, 2025, 58, 694-703.	1.2	0
837	Managing Patients With a History of Arterial Disease and New Venous Thromboembolism. Hematology, 2025, 2025, 22-33.	2.5	1
838	Updates in Antithrombotic Therapy in Coronary and Peripheral Artery Disease. Hematology, 2025, 2025, 34-38.	2.5	0
839	10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026. Diabetes Care, 2026, 49, S216-S245.	20.9	152
840	Thromboelastography to Support Clinical Decision Making in Patients With Peripheral Artery Disease. Diagnostics, 2025, 15, 3113.	4.9	1
841	Antithrombotic Therapy in Lower Extremity Peripheral Artery Disease Patients With Venous Thromboembolism: A Nationwide Cohort Study. Research and Practice in Thrombosis and Haemostasis, 2026, 10, 103291.	3.3	1
842	Management of Peripheral Artery Disease in Adults With Diabetes: 2025 ACC Scientific Statement: A Report of the American College of Cardiology. Journal of the American College of Cardiology, 2026, 88, 891-906.	12.0	15
843	Semaglutide Beyond Diabetes and Obesity: Systematic Review and Meta-Analysis of Multisystem Therapeutic Benefits. Endocrine Practice, 2026, 32, 623-635.	3.9	1
844	Efficacy of Dual Therapy With Aspirin and Rivaroxaban in Symptomatic Peripheral Artery Disease: The DOLOMITI Experience. International Angiology, 2025, 44, 486-496.	1.8	0
845	Gefäßmedizinische Rehabilitation bei Patienten mit peripher arterieller Verschlusskrankheit (pAVK). Geriatrie Up2date, 2026, 08, 53-67.	0.1	0
846	Dual Pathway Inhibition: Redefining the Secondary Prevention COMPASS in Chronic Coronary Artery Disease. International Journal of Angiology, 2025, .	1.1	0

#	Article	IF	Citations
847	The Internal Medicine Management of Diabetic Foot Syndrome. Minerva Medica, 2026, 117, 36-52.	0.8	3
848	Positionspapier der DDG, DGA, DGG und DeGiR zur Diagnostik und Behandlung der pAVK bei Diabetes mellitus. Diabetologie Und Stoffwechsel, 2025, 20, S454-S467.	0.2	0
849	A Systematic Review and Meta-Analysis of the Impact of Clopidogrel Responsiveness on Ischemic and Bleeding Complications After Noncoronary Endovascular Procedures. Journal of Vascular Surgery, 2026, 83, 1249-1258.e4.	3.4	4
850	Cardiac, Perioperative Risk Assessment. , 2025, .		0
851	Advancing Management of Patients With Lower Extremity Peripheral Artery Disease: A Focused Review and Our Institution's Approach to Postendovascular Intervention Care. American Journal of Cardiology, 2026, 261, 50-58.	2.4	0
852	The Impact of Common Thromboprophylactic Regimens on Thrombin Generation in Patients With Peripheral Artery Disease Postrevascularization. Annals of Vascular Surgery, 2026, 125, 112-121.	1.8	0
853	2026 ACC/AHA Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. Journal of the American College of Cardiology, 2026, 88, 856-890.	12.0	3
854	2026 ACC/AHA Clinical Performance and Quality Measures for Patients With Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Joint Committee on Performance Measures. , 2026, 19, e000142.		1
855	Vascular-POPS: Evidence for a New Standard of Care in the Management of Chronic Limb-Threatening Ischaemia. Age and Ageing, 2026, .	6.9	3
856	Effect of Rivaroxaban on DNA Damage in an Ischemia-Reperfusion Model: Evaluation of 8-OHdG Levels. Experimental and Therapeutic Medicine, 2026, 31, 1-7.	2.4	1
857	2026 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. Circulation, 2026, 153, e275-e906.	24.6	277
858	The Massachusetts General Hospital Protocols and Procedures for Venous Disease. , 2026, .		1
859	Церебропротекция при фибрилляции предсердий и различных сердечно-сосудистых заболеваниях: Возможности ривароксабана. Povedenčeskaâ Nevrologiâ, 2025, .	0.2	0
860	Peripheral Artery Disease in the Legs. New England Journal of Medicine, 2026, 394, 486-496.	76.6	14
861	Glucagon-Like Peptide-1 Receptor Agonists and Prior Major Adverse Limb Events in Patients With Diabetes. JAMA Network Open, 2026, 9, e2555952-e2555952.	10.2	5
862	Multifocal Atherosclerosis: The Possibilities of Antithrombotic Therapy. Scientific Bulletin of the Omsk State Medical University, 2024, 4, 2-12.	0.2	0
863	Positionspapier der DDG, DGA, DGG und DeGiR zur Diagnostik und Behandlung der pAVK bei Diabetes mellitus. Die Diabetologie, 2026, 22, 177-190.	0.1	0
864	Облитерирующий атеросклероз нижних конечностей: проблемы хирургического лечения и прогноз. Атеросклероз, 2025, 21, 429-439.	0.3	0

#	Article	IF	Citations
865	Low-Dose Rivaroxaban Plus Antiplatelet Therapy for Symptomatic Intracranial Atherosclerotic Stenosis: A Prospective Cohort Study. International Journal of Stroke, 2026, 21, 1130-1139.	7.4	2
866	Cardiovascular Disease: Sex and Gender Evidence for Cardiovascular Disease Prevention and Risk Factors for Ischemic Heart Disease, Heart Failure, Valvular Disease, Peripheral Arterial Disease; And Cardiovascular Disease in Pregnancy. , 2026, .		0
867	Multisite Artery Disease. , 2026, .		0
868	Medical Management of Peripheral Arterial Disease. Techniques in Vascular and Interventional Radiology, 2026, 29, 101100.	1.6	0
869	Methods Article for a Study Protocol: Study Design and Baseline Characteristics of the Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease (TRACK) Trial. American Journal of Nephrology, 2026, .	3.9	1
870	Leitlinienbasierte Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit. Die Chirurgie, 2026, 97, 251-260.	0.7	0
871	Antithrombotic Strategies After Lower Extremity Revascularization in Chronic Limb-Threatening Ischemia: A Systematic Review and Network Meta-Analysis. JVS-Vascular Insights: An Open Access Publication from the Society for Vascular Surgery, 2026, 4, 100381.	0.9	0
872	Restituire passi: il salvataggio d'arto. , 2026, La Chirurgia Vascolare dell'Ateneo Fio, 65-76.		0
873	Anticoagulants Beyond Coagulation: A Narrative Review of Cardiovascular Effects. Cardiovascular Research, 2026, 122, 562-577.	13.5	4
874	Arzneiverordnungs-Report 2025. , 2026, .		5
875	Alcohol Use Disorder Increases Risk of Major Adverse Limb Events Following Lower-Extremity Revascularization for Chronic Limb-Threatening Ischemia. Journal of Vascular Surgery, 2026, 83, 1649-1660.e2.	3.4	1
876	Timeless Therapeutics: Cardiac Indications for Vitamin K Antagonists in Clinical Practice. Heart, 2026, .	4.9	1
877	Low-Dose Rivaroxaban Plus Aspirin in Patients With PAD Undergoing Lower Extremity Revascularization With and Without History of Prior Limb Revascularization: Insight From the VOYAGER-PAD Trial. Circulation: Cardiovascular Interventions, 2026, 19, e015229.	6.2	1
878	Mechanisms of Symptomatic Lower Extremity Artery Disease in Femoropopliteal Arteries Assessed by Optical Frequency Domain Imaging. American Journal of Cardiology, 2026, 266, 174-180.	2.4	1
879	Impact of Dual-Pathway Inhibitor Therapy on Outcomes After Femoropopliteal In-Stent Occlusion. Cardiovascular Intervention and Therapeutics, 2026, 41, 660-669.	5.1	0
880	Effectiveness and Safety of Rivaroxaban Following Peripheral Arterial Endovascular Revascularization in Real-World Practice. Journal of Vascular Surgery, 2026, 84, 178-188.e10.	3.4	1
881	Peripheral Artery Disease in Persons With Type 2 Diabetes. , 2026, .		0
882	Categorization of Patients With Peripheral Artery Disease by Charlson Comorbidity Index. European Journal of Preventive Cardiology, 2026, .	6.1	3

#	Article	IF	Citations
883	Thrombus and Healing in Femoropopliteal Arterial Disease: Insights Into the Mechanisms of Symptomatic Peripheral Arterial Disease Progression. American Journal of Cardiology, 2026, 268, 176-177.	2.4	0
884	Antithrombotische Therapiestrategien in der Atherosklerose. Kardiologie Up2date, 2026, 22, 61-74.	0.0	0
885	Optimal Antithrombotic Regimens Across Atherosclerotic Vascular Beds: Toward Mechanism and Risk-Oriented Strategies. Journal of Clinical Medicine, 2026, 15, 2325.	3.8	3
886	Too Much, Too Little, or Just Right: Tailoring Postrevascularization Antithrombotic Therapy in PAD Versus CAD When One Size Does Not Fit All. Vascular Medicine, 2026, 31, 163-164.	2.3	1
887	Clinical Akrasia: The Evidence-Action Gap in Peripheral Artery Disease. Circulation: Cardiovascular Interventions, 2026, 19, e016677.	6.2	0
888	Safety and Efficacy of Escalating Antithrombotic Therapy After Lower Extremity Revascularization for Chronic Limb-Threatening Ischemia. Journal of Vascular Surgery, 2026, 84, 167-177.e2.	3.4	0
889	Characteristics and Outcomes of Patients With Diabetes Mellitus Selected for Dual Pathway Inhibition in Clinical Practice: The XATOA Registry. Vascular Medicine, 2026, 31, 493-504.	2.3	0
890	Diagnostic Ability of the Japanese Version of the High Bleeding Risk Criteria in Patients With Lower Extremity Peripheral Arterial Disease. Circulation Journal, 2026, 90, 515-521.	4.0	1
891	Sequential Dual Rotational Atherectomy for Salvage of a 20-Year Axillobifemoral PTFE Graft. Journal of Vascular Surgery Cases and Innovative Techniques, 2026, 12, 102238.	0.9	0
892	Sirolimus-Coated Balloon Angioplasty for Infrainguinal Artery Disease. New England Journal of Medicine, 2026, 395, 561-570.	76.6	5
893	High-Sensitivity Thrombin Generation Profiling Identifies Divergent Coagulation States Across Peripheral Artery Disease Severity. Thrombosis Update, 2026, 22, 100235.	1.6	1
894	Adaptation of the Transtibial Tunnel Technique for Limb Salvage Arterial Bypass With Anatomic Challenges. European Journal of Vascular and Endovascular Surgery, 2026, 71, 1106-1107.	3.2	0
895	Development and Validation of Risk Scores in Vascular Diseases. , 0, .		0
896	Mise au point et optimisation d'un modèle lagomorphe hypercholestérolémique de resténose intra-stent et application pour le développement d'un stent obtenu par électrofilage. , 0, .		0
897	Impact of Peripheral Arterial Disease and Cerebrovascular Disease on Outcomes in Patients Undergoing PCI. IJC Heart and Vasculature, 2026, 64, 101920.	2.6	0
898	Rôle de la maladie microvasculaire dans la physiopathologie de l'artériopathie oblitérante des membres inférieurs. , 0, .		0
899	Artériopathie des membres inférieurs chez le patient vivant avec un diabète de type 2 : marqueurs du risque et impact des thérapeutiques. , 0, .		0
900	Peripheral Artery Disease Treatment: Scoping Review With ❁SAIMSARA. , 2026, .		0

#	Article	IF	Citations
901	Major Amputations and the Compound Risk of Peripheral Arterial Disease Following Minor Amputation. JVS-Vascular Insights: An Open Access Publication from the Society for Vascular Surgery, 2026, 4, 100422.	0.9	1
902	Impact of Concurrent Antiplatelet Use on the Safety and Efficacy of Thromboprophylaxis With Apixaban in Patients With Cancer: A Post-Hoc Analysis of the AVERT Trial. Thrombosis Research, 2026, 261, 109681.	2.9	0
903	Cost-Effectiveness of Antithrombotic Therapies for Peripheral Arterial Disease. Journal of Vascular Surgery, 2026, 84, 448-458.e3.	3.4	0
904	Mechanisms of Interaction Between the Blood Coagulation System and Atherosclerosis in Lower Extremity Peripheral Artery Disease. Kreativnaâ Hirurgiâ I Onkologiâ, 2026, 16, 71-80.	0.4	0
905	Timing of Restenosis and Reocclusion Following Endovascular Therapy for Femoropopliteal Lesions. Cureus, 2026, 18, e107342.	1.3	0
906	Peripheral Artery Disease in Diabetes. Frontiers in Endocrinology, 2026, 17, 1811582.	5.8	3
907	Revaskularisation und Amputationsrisiko bei pAVK und Diabetes mellitus. Geriatrie Up2date, 2026, 08, 121-132.	0.1	0
908	Tratamiento Anticoagulante Oral. FMC Formacion Medica Continuada En Atencion Primaria, 2026, 33, 9-39.	0.1	0
909	Community-Based Recruitment With Ankle Brachial Index Testing to Identify Peripheral Artery Disease Participants for Randomized Clinical Trials. American Heart Journal, 2026, 300, 107450.	3.3	1
910	Clinical and Patient-Reported Outcomes After Drug-Coated Balloon Angioplasty for Femoropopliteal Peripheral Artery Disease. Vasa - European Journal of Vascular Medicine, 2026, .	2.7	2
911	When Nerves and Arteries Collide: Shared Biology, Diagnostic Pitfalls, and Integrated Care for Neuropathy and Peripheral Artery Disease. , 2026, 1, 30.		0
912	Secondary Prevention Strategies for Patients With Lower Extremity Peripheral Artery Disease After Successful Peripheral Vascular Intervention. American Heart Journal, 2026, 299, 107446.	3.3	1
913	Arterial Thromboembolism. , 2026, .		0
914	Eligibility for Dual Pathway Inhibition in Patients With Peripheral Artery Disease Undergoing Revascularization. Journal of Cardiovascular Medicine, 2026, 27, 306-317.	2.3	2
915	Gaps in Incidence and Design of Peripheral Versus Coronary Artery Disease Clinical Trials. Journal of Surgical Research, 2026, 323, 24-32.	1.8	0
916	Peripheral Artery Disease and Amputation: Scoping Review With ❄SAIMSARA. , 2026, .		0
917	Revascularization Strategies and Outcomes in Critical Limb Ischemia: A Four-Year Retrospective Study of 65 Patients in a Sub-Saharan Cardiovascular Surgery Center. International Journal of Cardiovascular and Thoracic Surgery, 2026, 12, 85-91.	0.1	0
918	Transformative Advances in Vascular Surgery: Five Decades of Innovation in the Management of Aortic, Carotid, and Peripheral Arterial Disease. World Journal of Surgery, 2026, 50, 2092-2096.	2.7	0

#	Article	IF	Citations
919	Potential Bias in Efficacy Estimates Due to Intercurrent Treatment Discontinuations. European Heart Journal Quality of Care & Clinical Outcomes, 2026, 12, 1011-1022.	4.9	1
920	Limb Salvage Outcomes Following Below-the-Knee Angioplasty in Chronic Limb-Threatening Ischemia: A Single-Center Experience From India. Indian Journal of Vascular and Endovascular Surgery, 2026, 13, 221-224.	0.3	0
921	Therapeutic Strategies Combining Antiplatelet With Anticoagulant Actions: Heparin Proteoglycan Mimetic APAC as a Model. Arteriosclerosis, Thrombosis, and Vascular Biology, 2026, 46, e323844.	7.9	0
922	Low-Dose Rivaroxaban and Cardiovascular Events in Advanced Kidney Disease: The TRACK Randomized Clinical Trial. JAMA - Journal of the American Medical Association, 2026, 336, 296-305.	37.0	8
923	Efficacy and Safety of Rivaroxaban Plus Aspirin Compared With Aspirin Alone in Patients With Peripheral Arterial Disease: A Systematic Review and Meta-Analysis. Annals of Medicine and Surgery, 2026, 88, 4437-4447.	1.7	0
924	Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. Circulation, 2026, 154, e188-e205.	24.6	2
925	Defining Cardiovascular Endpoints in Oncology Trials: Challenges and Opportunities: A Scientific Statement From the American Heart Association. Journal of Clinical Oncology, 2026, 44, 2140-2155.	23.9	1
926	Optimal Antithrombotic Therapy for Peripheral Artery Disease: A Systematic Review and Network Meta-Analysis. Journal of the American Heart Association, 2026, 15, e047301.	5.8	0
927	LDL Cholesterol Control in Patients With Atherosclerotic Carotid Stenosis›50%, Previous Endarterectomy or Carotid Stent. Clínica E Investigación En Arteriosclerosis, 2026, .	1.3	0
928	Analysis of Dual Pathway Inhibition Prescription After Percutaneous Vascular Intervention. JVS-Vascular Insights: An Open Access Publication from the Society for Vascular Surgery, 2026, 4, 100472.	0.9	0
929	Endovascular Revascularisation of Lower-Extremity Peripheral Arterial Disease: Technical and Clinical Outcomes in a Vietnamese Single-Center Prospective Cohort Study. Future Cardiology, 2026, 22, 707-716.	1.2	0
930	Predictors of Target Lesion Restenosis After Endovascular Therapy for Lower-Extremity Atherosclerotic Peripheral Artery Disease: A Real-World Single Center Cohort. Journal of Cardiothoracic Surgery, 2026, 21, 659.	1.7	0
931	Home-Based Intravenous Iloprost by Portable Elastomeric Pump in Chronic Limb-Threatening Ischemia: A Pilot Study. Vascular Medicine, 2026, 31, 526-534.	2.3	0
932	Advances, Challenges, and Future Perspectives in the Diagnosis and Treatment of Chronic Venous Disorder: A Comprehensive Review. Medicine in Novel Technology and Devices, 2026, 31, 100449.	4.5	0
933	Analysis of Patient Presentation to the ED Within 90-Days of Infra-Inguinal Bypass. Annals of Vascular Surgery, 2026, 132, 275-283.	1.8	0
934	Rivaroxaban for the Prevention of Atherothrombotic Events in Advanced CKD: Are We Off TRACK?. CKJ: Clinical Kidney Journal, 2026, 19, sfag220.	4.8	1
935	Antiplatelet Therapy in the Management of Atherosclerotic Cardiovascular Disease: 2026 ACC Scientific Statement: A Report of the American College of Cardiology. Journal of the American College of Cardiology, 2026, 88, 1284-1313.	12.0	3
936	Validation of the European Society of Cardiology Ischemic and Bleeding Risk Criteria for Risk Stratification After Endovascular Therapy in Japanese Patients With Lower Extremity Artery Disease. Catheterization and Cardiovascular Interventions, 2026, 108, 801-815.	2.2	0

#	Article	IF	Citations
937	Premature Peripheral Arterial Disease Is Associated With Worse Outcomes After Endovascular Peripheral Vascular Intervention. Journal of Vascular Surgery, 2026, 84, 1266-1274.	3.4	0
938	Umstellung antithrombozytärer Therapien: Interaktionen und praktische Durchführung – DGK-Empfehlung. Die Kardiologie, 2026, 20, 377-389.	1.4	0
939	Impact of 1-Month Dual Antiplatelet Therapy After Treatment With Drug-Coated Balloon for Femoropopliteal Artery Disease. Heart and Vessels, 2026, .	1.8	2
940	Comparative Effectiveness of Dual Antiplatelet Therapy After Revascularization in Diabetes and Chronic Limb-Threatening Ischemia: A Target Trial Emulation Study. Cardiovascular Diabetology, 2026, .	15.7	1
941	Effect of Low-Dose Rivaroxaban Plus Aspirin on 18F-FDG PET/CT-Detectable Carotid Plaque Inflammation: A Randomized Trial. European Heart Journal Cardiovascular Imaging, 2026, 27, 1728-1740.	4.7	0
942	Impact of Postoperative Antithrombotic Treatment on Patency and Survival After Open Posterior Popliteal Artery Aneurysm Repair: A Multicenter Retrospective Cohort Analysis From the PARADE Study. Journal of Clinical Medicine, 2026, 15, 5364.	3.8	0
943	Auryon 355 nm Laser Atherectomy for Femoropopliteal In-Stent Occlusions: A Retrospective Comparative Study of Technical Success and 12-Month Outcomes. Biomedicines, 2026, 14, 1538.	4.9	1
944	Perioperative Antithrombotic Management in Major Vascular Surgery: A Narrative Review of Competing Thrombotic and Hemorrhagic Risks. Annals of Vascular Surgery, 2026, 132, 636-651.	1.8	0
945	Vascular Pathologies in the Surgical ICU. , 2026, .		0
946	Impact of Paclitaxel Coated Devices on Limb Salvage and Target Vessel Revascularisation Rates Following Isolated Femoropopliteal or Infrapopliteal Endovascular Revascularisation for Chronic Limb Threatening Ischaemia: Insights From the SWEDEPAD 1 Trial. European Journal of Vascular and Endovascular Surgery, 2026, .	3.2	0
947	Pleiotropic Effects of Direct Oral Anticoagulants on the Coagulation-Inflammation-Endothelium Axis: A Phenotype-Stratified Narrative Review. Biomedicine and Pharmacotherapy, 2026, 202, 119768.	9.8	0
948	Peripheral Artery Disease: Advances in Medical Therapy. European Heart Journal, 2026, .	14.7	2
949	Peripheral Stent Thrombosis: Impact of Anticoagulation Strategies and Diagnostic Role of Platelet Aggregometry. Vasa - European Journal of Vascular Medicine, 2026, .	2.7	0
950	Advances in the Diagnosis and Treatment of Acute Limb Ischemia in the Era of Intracavitary Minimally Invasive Techniques. Advances in Clinical Medicine, 2026, 16, 2254-2266.	0.1	0
951	Long-Term Antithrombotic Therapy in Patients With Short Bowel Syndrome: A European Society for Clinical Nutrition and Metabolism (ESPEN) Position Paper.. Clinical Nutrition, 2026, 64, 106741.	7.5	0
952	Accuracy of Multimodal Intravascular Imaging in Evaluating Neointimal Tissue in a Swine Femoropopliteal Artery Stent Model. Cardiovascular Intervention and Therapeutics, 2026, 41, 1077-1086.	5.1	0
953	Long-Term Antithrombotic Therapy After Percutaneous Coronary Intervention: Secondary Prevention Beyond One Year. Reviews in Cardiovascular Medicine, 2026, 27, 51947.	2.5	0
954	Optimal Strategy for Treatment of Atherosclerotic Cardiovascular Disease—Comparison of Clopidogrel-Based Antiplatelet Agent Treatment Versus Aspirin Plus Low Dose Rivaroxaban Therapy (OACART Study): A Study Protocol for a Multicenter, Open-Label, Randomized, Non-Inferiority Trial. Trials, 2026, .	2.6	0

#	Article	IF	Citations
955	Dual Antiplatelet Therapy Is Not Associated With Target Vessel Occlusion or Bleeding Complications Following Fenestrated and Branched Aortic Repair. Journal of Vascular Surgery, 2026, .	3.4	0
956	Care of the Older Adult. , 2026, .		0
957	CYP2C19 Loss-of-Function Carriers Have Increased Risk of Cardiac, but Not Limb, Events Following Clopidogrel Treatment for Peripheral Artery Disease Revascularization. JVS-Vascular Insights: An Open Access Publication from the Society for Vascular Surgery, 2026, 4, 100529.	0.9	0
958	Drug-Eluting Balloon Angioplasty Versus Uncoated Balloon Angioplasty for Peripheral Arterial Disease of the Lower Limbs. Cochrane Database of Systematic Reviews, 2026, 8, CD011319.	6.9	1
959	Quality of Life Assessment in Patients With Obliterating Atherosclerosis of the Lower Extremity Arteries. , 2026, .		0
960	Functional Clopidogrel Resistance and CYP2C19 Genetic Determinants After Lower Limb Endovascular Intervention: A Systematic Review and Meta-Analysis of Clinically Relevant Outcomes. Clinical Therapeutics, 2026, .	3.4	0
961	Platelet Reactivity and Sex Differences: Clinical Implications for Women. Circulation Research, 2026, 139, e328602.	15.7	0
962	Trends in Peripheral Vascular Disease-Related Mortality Among U.S. Adults With Co-Listed Hypertension and Type 2 Diabetes, 1999-2023: A Retrospective Observational Study. Medicine (United States), 2026, 105, e50159.	2.1	0
963	Current Updates in Chronic Limb-Threatening Ischemia and Peripheral Arterial Disease Management. International Journal of Lower Extremity Wounds, 2026, .	2.0	1
964	Bempedoic Acid and First and Recurrent Limb Outcomes in Statin-Intolerant Patients With Peripheral Artery Disease: Insights From the CLEAR Outcomes Trial. Circulation, 2026, 154, 966-975.	24.6	2
965	Impact of Atrial Fibrillation on Heart Failure-Related Events After Endovascular Therapy for Peripheral Artery Disease. Heart and Vessels, 2026, .	1.8	0
966	Letter to the Editor: Unaddressed Research Gaps in Antithrombotic Therapy Following Drug-Coated Balloon Angioplasty for Peripheral Artery Disease. Heart and Vessels, 2026, .	1.8	0
967	Authors' Reply to "Unaddressed Research Gaps in Antithrombotic Therapy Following Drug-Coated Balloon Angioplasty for Peripheral Artery Disease". Heart and Vessels, 2026, .	1.8	0
968	Great Strides...Now It's Time to Run. Journal of the American College of Cardiology, 2026, 88, 907-909.	12.0	0
969	The Diagnosis and Current Treatment of Chronic Lower Extremity Arterial Disease. Future Cardiology, 2026, 22, 737-752.	1.2	0
970	Dual Pathway Inhibition Versus Dual Antiplatelet Therapy in Patients With Acute or Nonacute Limb Ischemia: A Propensity Score-Matched Analysis From the RESOLVE Study. Journal of Vascular Surgery, 2026, .	3.4	0
971	Dual Pathway Inhibition Versus Dual Antiplatelet Therapy Following Isolated Tibial Balloon Angioplasty for Chronic Limb-Threatening Ischemia. Journal of Vascular Surgery, 2026, .	3.4	0
972	Rivaroxaban. , 2026, .		0

#	Article	IF	Citations
973	Results of Repeat Open Revascularization Procedures in Patients With Occlusive-Stenotic Lesions of the Lower Extremity Arteries. Клінічна та профілактична медицина, 2026, .	0.4	0
974	A Four-Gene Cuproptosis mRNA Multi-Channel Electrochemical Sensing Array for Molecular Subtyping of Atherosclerotic Plaques in Peripheral Artery Disease. Microchemical Journal, 2026, 229, 119582.	5.2	0
975	Thromboelastography With Platelet Mapping-Guided Thromboprophylaxis in Patients With Diabetes Undergoing Infrainguinal Endovascular Revascularization. Annals of Vascular Surgery, 2026, 133, 778-790.	1.8	1
976	Association of Dual-Pathway Antithrombotic Therapy With Primary Patency After Iliofemoral Venous Stenting: A Multicenter Cohort Study. Research and Practice in Thrombosis and Haemostasis, 2026, 10, 106965.	3.3	0
977	Vascular Quality Initiative Based Risk Score for Mortality Within 3 Years of Revascularization for Chronic Limb Threatening Ischemia in End Stage Renal Disease Patients on Dialysis. Journal of Vascular Surgery, 2026, .	3.4	1
978	One-Year Mortality, Cardiovascular and Limb Events in the BEST-CLI Registry of Chronic Limb Threatening Ischemia Patients. Journal of Vascular Surgery, 2026, .	3.4	0
979	Semaglutide and Limb Events: Expanding the Cardiovascular Prevention Paradigm?. European Journal of Preventive Cardiology, 2026, .	6.1	0
980	The Peripheral Arterial Bleeding (PAB) Classification: A Novel Classification for Safety Reporting in Peripheral Arterial Disease - An International Delphi Consensus Study. Annals of Vascular Surgery, 2026, 134, 301-309.	1.8	0
981	Current Advancements in the Care of Peripheral Arterial Disease: Modern Approaches to Medical, Endovascular, and Surgical Treatment. Lancet, The, 2026, 408, 1371-1382.	96.9	2
982	From One Plaque to Many: The Coming Tsunami of Pan-Vascular Disease: Bringing Pan-Vascular Disease to the Centre of Cardiovascular Prevention. Cardiovascular Research, 2026, 122, 1728-1731.	13.5	0
983	Predictive Value of Ankle-Brachial Index Variability for Symptom Progression in Peripheral Arterial Disease: A Prospective Cohort Study. International Angiology, 2026, .	1.8	0
984	Persistent Disparities and Undertreatment With Antithrombotic Therapy After Peripheral Revascularisation in Korea: A 14 Year Nationwide Cohort Study. European Journal of Vascular and Endovascular Surgery, 2026, .	3.2	0
985	CIRSE Standards of Practice for the Endovascular Management of Acute Lower Limb Ischaemia. CardioVascular and Interventional Radiology, 2026, .	2.3	0
986	Conduit Type Is Associated With Distinct Fibrin-Mediated Coagulation Trajectories Following Lower Extremity Bypass. JVS Vascular Science, 2026, 7, 100451.	1.8	0
987	Leitlinienbasierte Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit. Gefasschirurgie, 2026, 31, 561-570.	0.4	0
988	Leitlinienbasierte Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit. Zeitschrift Fur Herz-, Thorax- Und Gefasschirurgie, 2026, .	0.1	0
989	Medical Management of Vascular Disease—Including Pharmacology of Drugs Used in Vascular Disease Management. , 2027, .		0
990	Natural History and Nonoperative Treatment of Intermittent Claudication. , 2027, .		0

#	Article	IF	Citations
991	Venous Thromboembolic Disease. , 2027, .		0
992	Peripheral Arterial Disease. , 2026, .		0
993	PAD as a Marker of Systemic Atherosclerosis: A Comprehensive Review of Residual Risk and Contemporary Strategies for MACE and MALE Reduction. Medicina (Lithuania), 2026, 62, 1905.	3.3	0
994	Антитромбоцитарна терапія в лікуванні атеросклеротичних серцево-судинних захворювань. Ukrainian Medical Journal, 2026, .	0.1	0
995	Pathway-Guided and Patient-Centred Therapeutic Strategies in Atherosclerotic Cardiovascular Disease. European Journal of Preventive Cardiology, 2026, .	6.1	0
996	Heart Failure Predicts Contralateral Limb Progression After Endovascular Therapy for Initial Unilateral Chronic Limb-Threatening Ischemia. Journal of Endovascular Therapy, 2026, .	2.1	0
997	Low-Dose Drug-Coated Balloon Treatment Effectively Maintains 1-Year Clinical Patency in Korean Patients With Femoropopliteal Artery Lesions: There Is Still Room for Improvement. Korean Circulation Journal, 2027, .	1.7	0
998	The Start-SIAPAV-PAD Registry – Rationale, Study Design, and Baseline Characteristics of an Ongoing Italian Multicentre Registry. Vasa - European Journal of Vascular Medicine, 2026, .	2.7	0
999	Polyvascular Atherosclerotic Disease Across Contemporary ESC Guidelines: Key Updates, Clinical Gaps, and Future Perspectives. Medicina (Lithuania), 2026, 62, 2047.	3.3	0
1000	A Durable Limb Salvage and Functional Recovery After Prolonged Prostaglandin E1 Therapy Following Femoro-Popliteal Bypass Graft Thrombosis: A One-Year Follow-Up Case Report. International Surgery Journal, 2026, 13, 2253-2257.	0.2	0